Skip to main content
SpringerLink
Log in

Atemwegserkrankung

  • Chapter
Cystische Fibrose

  • 163 Accesses

Zusammenfassung

Es wird immer noch angenommen, dass Kinder mit cystischer Fibrose (CF) mit histoanatomisch normalen Lungen zur Welt kommen [30]. Zweifelsohne beginnt sich aber der pulmonale Befall bei den meisten Patienten immunologisch und funktionell bereits in den ersten Lebensmonaten zu manifestieren. Im Vordergrund steht bereits in diesem Alter einerseits die Imbalance zwischen Proteasen (Leukozytenelastase) und Antiproteasen (α1-Antitrypsin etc.) im Schleimhautfilm des Bronchialtraktes [4]. Andererseits ist lungenphysiologisch bei vielen Säuglingen eine pulmonale Überblähung festzustellen, ein Befund, welcher klinisch über Monate verborgen bleiben kann, und vom Genotyp abhängig zu sein scheint [13]

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu

Liteatur zu 7.1

  1. Aebi C, Bracher R, Liechti Gallati S, Tschappeler H, Rudeberg A, Kraemer R (1995) The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis — prognostic significance. Eur J Pediatr 154:S69–S73

    PubMed  CAS  Google Scholar 

  2. Beardsmore CS (1995) Lung function from infancy to school age in cystic fibrosis. Arch Dis Child 73:519–523

    PubMed  CAS  Google Scholar 

  3. Beardsmore CS, Wimpress SP, Thomson AH, Patel HR, Goodenough P, Simpson H (1987) Maximum voluntary cough: an indication of airway function. Bull Eur Physiopathol Respir 23:465–472

    PubMed  CAS  Google Scholar 

  4. Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti Gallati S, Kraemer R, Hubbard R, Crystal RG (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150:207–213

    PubMed  CAS  Google Scholar 

  5. Boat TF, Cheng PW (1989) Epithelial cell dysfunction in cystic fibrosis: implications for airways disease. Acta Paediatr Scand Suppl 363:25–29

    PubMed  CAS  Google Scholar 

  6. Chrispin AR, Norman AP (1974) The systematic evaluation of the chest radiograph in CF. Pediatr Radiol 2:101–104

    PubMed  CAS  Google Scholar 

  7. Davis PB, Drumm M, Konstan MW (1996) Cystic fibrosis. Am J Respir Crit Care Med 154:1229–1256

    PubMed  CAS  Google Scholar 

  8. Gibson LE, Cooke RE (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing Pilocarpine by iontophoresis. Pediatrics 23:545–549

    PubMed  CAS  Google Scholar 

  9. Hordvik NK, Koenig P, Morris D, Kreutz C, Barbero GF (1985) A longitudinal study of bronchodialtor responsiveness in cystic fibrosis. Am Rev Respir Dis 131:889–893

    PubMed  CAS  Google Scholar 

  10. Imundo L, Barasch J, Prince A, Al Awqati Q (1995) Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface (published erratum appears in Proc Natl Acad Sci USA 92 (24): 11322). Proc Natl Acad Sci USA 92:3019–3023

    PubMed  CAS  Google Scholar 

  11. Jiang X, Hill WG, Pilewski JM, Weisz OA (1997) Glycosylation differences between a cystic fibrosis and rescued airway cell line are not CFTR dependent. Am J Physiol 273: L913–L920

    PubMed  CAS  Google Scholar 

  12. Kraemer R (1993) Assessment of functional abnormalities in infants and children with lung disease. Agents Actions Suppl 40

    Google Scholar 

  13. Kraemer R, Birrer P, Liechti Gallati S (1998) Genotype-phenotype association in infants with cystic fibrosis at the time of diagnosis. Pediatr Res 44:920–926

    PubMed  CAS  Google Scholar 

  14. Kraemer R, Modelska K, Casaulta Aebischer C, Schöni MH (1991) A new baby-spacer device for aerosolized bronchodilator administration in infants with bronchopulmonary disease. Eur J Pediatr 151:57–60

    Google Scholar 

  15. Kraemer R, Rüdeberg A, Klay M, Rossi E (1979) Relation-ship between clinical conditions, radiographic findings and pulmonary functions in patients with cystic fibrosis. Helv Paediatr Acta 34:417–428

    PubMed  CAS  Google Scholar 

  16. Kraemer R, Schöni MH (1990) Ventilatory inequalities, pulmonary function and blood oxygenation in advanced states of cystic fibrosis. Respiration 57:318–324

    PubMed  CAS  Google Scholar 

  17. Kraemer R, Tschappeler H, Rüdeberg A, Stoll E, Rossi E (1979) Course and quantitative evaluation of the lung involvement in cystic fibrosis. Schweiz Med Wochenschr 109:39–45

    PubMed  CAS  Google Scholar 

  18. Kraemer R, Zehnder M, Meister B (1986) Intrapulmonary gas distribution in healthy children. Respir Physiol 65: 127–137

    PubMed  CAS  Google Scholar 

  19. Liechti Gallati S, Bonsall I, Malik N, Schneider V, Kraemer LG, Rüdeberg A, Moser H, Kraemer R (1992) Genotype/phenotype association in cystic fibrosis: analyses of the delta F508, R553X, and 3905insT mutations. Pediatr Res 32:175–178

    PubMed  CAS  Google Scholar 

  20. Liechti-Gallati S, Schneider V, Neeser D, Kraemer R (1999) Two buffer PAGE System bared SSCP/HD analysis: A general protocol for rapid and sensitive mutation Screening in cystic fibrosis and any other human genetic disease. Eur J Hum Genet 7:590–598

    PubMed  CAS  Google Scholar 

  21. Liedtke D, Casaulta Aebischer C, Martin N, Kraemer R (2000) Effizienz physiotherapeutischer Atem- und Inhalationstherapie bei Patienten mit zystischer Fibrose. Bronchodilatatoren vor oder nach Atemphysiotherapie? Physiotherapie 7:16–22

    Google Scholar 

  22. Loughlin GM, Cota KA, Taussig LM (1981) The relationship between flow transients and bronchial lability in cystic fibrosis. Chest 79:206–210

    PubMed  CAS  Google Scholar 

  23. Mearns MB, Hunt GH, Rushworth R (1972) Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950–71. Arch Dis Child 47:902–907

    PubMed  CAS  Google Scholar 

  24. Nixon PA, Orenstein D (1992) Prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 327: 1785–1788

    PubMed  CAS  Google Scholar 

  25. Orenstein DM, Nixon PA (1991) Exercise Performance and breathing patterns in cystic fibrosis: male- female differences and influence of resting pulmonary function. Pediatr Pulmonol 10:101–105

    PubMed  CAS  Google Scholar 

  26. Schwab UE, Wold AE, Carson JL, Leigh MW, Cheng PW, Gilligan PH, Boat TF (1993) Increased adherence of Staphylococcus aureus from cystic fibrosis lungs to airway epithelial cells. Am Rev Respir Dis 148:365–369

    PubMed  CAS  Google Scholar 

  27. Schöni MH, Kraemer R, Bähler P, Rossi E (1984) Early diagnosis of cystic fibrosis by means of sweat microosmometry. J Pediatr 104:691–694

    PubMed  Google Scholar 

  28. Sobonya RE, Taussig LM (1986) Quantitative aspects of lung pathology in cystic fibrosis. Am Rev Respir Dis 134: 290–295

    PubMed  CAS  Google Scholar 

  29. Stark JM, Amin RS, Trapnell BC (1996) Infection of A549 cells with a recombinant adenovirus vector induces ICAM-1 expression and increased CD-18-dependent adhesion of activated neutrophils. Hum Gene Ther 7:1669–1681

    PubMed  CAS  Google Scholar 

  30. Sturgess J, Imrie J (1982) Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 106:303–311

    PubMed  CAS  Google Scholar 

  31. Tepper RS, Hiatt P, Eigen H, Scott P, Grosfeld J, Cohen M (1988) Infants with cystic fibrosis: pulmonary function at diagnosis. Pediatr Pulmonol 5:15–18

    PubMed  CAS  Google Scholar 

  32. Tomashefski JF, Bruce M, Goldberg HI, Dearborn GG, Tandler B (1986) Regional distribution of macroskopic lung disease in cystic fibrosis. Am Rev Respir Dis 133: 535–540

    PubMed  Google Scholar 

  33. Wagener JS, Taussig JM, Burrows B, Hernried L, Boat T (1980) Comparison of lung function and survival patterns between cystic fibrosis and emphysema of chronic bronchitis patients. In: Sturgess JM (ed) Perspectives in cystic fibrosis. Imperial Press, Mississanga, Ontario, pp 236–245

    Google Scholar 

  34. Wood RE, Wanner A, Hirsch J, Farrell PM (1975) Tracheal mucociliary transport in patients with cystic fibrosis and its Stimulation by terbutaline. Am Rev Respir Dis 111: 733–738

    PubMed  CAS  Google Scholar 

  35. Zeulzer WW, Newton WA (1982) The pathogenesis of fibrocystic disease of the pancreas. A study of 36 cases with special reference to the pulmonary lesions. Pediatrics 4: 53–69

    Google Scholar 

Liteatur zu 7.2

  1. Abman SH, Ogle JW, Harbeck RJ et al. (1991) Early bacteriology, immunologic and clinical courses of young infants with cystic fibrosis identified by neonatal Screening. J Pediatr 119:211–217

    PubMed  CAS  Google Scholar 

  2. Albelda SM, Smith CW, Ward PA (1994) Adhesion molecules and inflammatory injury. FASEB J 8:504–512

    PubMed  CAS  Google Scholar 

  3. Anwar H, Strap JL, Costerton JW (1992) Susceptibility of biofilm cells of Pseudomonas aeruginosa to bactericidal actions of whole blood and serum. FEMS Microbiol Lett 71(3):235–241

    PubMed  CAS  Google Scholar 

  4. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD (1995) Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 310:1571–1572

    PubMed  CAS  Google Scholar 

  5. Armstrong DS, Grimwood K, Carlin JB et al. (1996) Bronchoalveolar lavage or oropharygeal cultures to identify lower respiratory pathogens in infants with CF. Pediatr Pulmonol 21:267–275

    PubMed  CAS  Google Scholar 

  6. Bayer AS, Speert DP, Park S et al. (1991) Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leucocyte-mediated killing of Pseudomonas aeruginosa. Infect Immunol 59(1): 302–308

    CAS  Google Scholar 

  7. Birrer P, McElvaney NG, Rüdeberg A, Wirz Sommer C, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 150: 207–213

    PubMed  CAS  Google Scholar 

  8. Bonfield TL, Konstan M, Burfeind P et al. (1995) Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine IL-10 which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 13:257–261

    PubMed  CAS  Google Scholar 

  9. Oppenheimer EH, Esterly JR (1973) Myocardial lesions in patients with cystic fibrosis of the pancreas. Hopkins Med J 133:252–261

    CAS  Google Scholar 

  10. Paditz E, Reitermeier G, Leupold W, Paul KD, Heinicke D, Reuner I, Dinger J, Schwarze R (1996) Nichtinvasive nächtliche nasale Masenbeatmung (NIPPV) im Kindes- und Jugendalter. Med Klin 91 (Suppl 2): 31–33

    Google Scholar 

  11. Padman R, Lawless S, Von Nessen S (1994) Use of BiPAP by nasal mask in the treatment of respiratory insufficiency in pediatric patients: preliminary investigations. Pediatr Pulmonol 17:119–123

    PubMed  CAS  Google Scholar 

  12. Panidis IP, Ren J-F, Holsclaw DS, Kotler MN, Mintz GS, Ross J (1985) Cardiac function in patients with cystic fibrosis: evaluation by two-dimensional and Doppler echocardiography. J Am Coli Cardiol 6:701–706

    CAS  Google Scholar 

  13. Pianosi P, Pelech A (1996) Stroke volume during exercise in cystic fibrosis. Am J Respir Crit Care Med 153:1105–1109

    PubMed  CAS  Google Scholar 

  14. Piepsz A, Harn HR, Millet E, Dab I (1987) Determination of right ventricular ejection fraction in children with cystic fibrosis. Pediatr Pulmonol 3:24–28

    PubMed  CAS  Google Scholar 

  15. Piper AJ, Parker S, Torzillo PJ, Sullivan CE, Bye PT (1992) Nocturnal nasal IPPV stabilizes patients with cystic fibrosis and hypercapnic respiratory failure. Chest 102:846–850

    PubMed  CAS  Google Scholar 

  16. Royce SW (1951) Cor pulmonale in infancy and early childhood: report on 34 patients, with special reference of pulmonary heart disease in cystic fibrosis of the pancreas. Pediatrics 8:255–274

    PubMed  CAS  Google Scholar 

  17. Salzer-Muhar U, Burghuber OC, Weissei M, Götz M (1988) Nichtinvasive Beurteilung der pulmonalen Hypertension mit Hilfe gepulster Doppler-Sonographie bei erwachsenen Patienten mit zystischer Fibrose. Prax Klin Pneumol 42:580–582

    PubMed  CAS  Google Scholar 

  18. Schidlow DV, Taussig LM, Knowles MR (1993) Cystic fibrosis foundation consensus Conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 15:187–198

    PubMed  CAS  Google Scholar 

  19. Stern RC, Borkat G, Hirschfeld SS, Boat TF, Matthews LW, Liebman J, Doershuk CF (1980) Heart failure in cystic fibrosis: treatment and prognosis of cor pulmonale with failure of the right side of the heart. Am J Dis Child 134: 267–272

    PubMed  CAS  Google Scholar 

  20. Sullivan MM, Moss RB, Hindi RD, Lewiston NJ (1986) Supraventricular tachycardia in patients with cystic fibrosis. Chest 90:239–242

    PubMed  CAS  Google Scholar 

  21. Tepper RS, Skatrud JB, Dempsey JA (1983) Ventilation and oxygenation changes during sleep in cystic fibrosis. Chest 84:388–393

    PubMed  CAS  Google Scholar 

  22. Venuta F, Rendina EA, Rocca GD, De Giacomo T, Pugliese F, Vizza CD, Coloni GF, Patterson GA (2000) Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. J Thorac Cardiovasc Surg 119:682–689

    PubMed  CAS  Google Scholar 

  23. Versteegh FGA, Neijens HJ, Bogaard JM, Stam H, Robijn RJ, Kerrebijn KF (1986) Relationship between pulmonary function, 02 Saturation during sleep and exercise, and exercise responses in children with cystic fibrosis. Adv Cardiol 35:151–155

    PubMed  CAS  Google Scholar 

  24. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP (1998) Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 113:576–583

    PubMed  CAS  Google Scholar 

  25. Boucher RC (1992) Drug therapy in the 1990’s, whatcanwe expect for cystic fibrosis. Drugs 43:431–43

    PubMed  CAS  Google Scholar 

  26. Cassino RJ, Sordelli DO, Macri CN et al. (1980) Pulmonary non specific defense mechanisms in cystic fibrosis: I, phagocytic capacity of alveolar macrophages and neutrophils. Pediatr Res 14(11): 1212–1215

    PubMed  CAS  Google Scholar 

  27. Chernik V, Kendig E (eds.) (1990) Disorders of the respiratory tract, 5th edn. Saunders, Philadelphia, pp 2–77

    Google Scholar 

  28. Dibbert B, Weber M, Nikolaizik WH, Vogt P, Schöni MH, Blaser K, Simon HU (1999) Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: A general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci USA 96:13330–13335

    PubMed  CAS  Google Scholar 

  29. DiMango E, Zar HJ, Bryan R et al. (1995) Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 96: 2204–2210

    PubMed  CAS  Google Scholar 

  30. Harper TB, Gaumer HR, Waring W et al. (1980) Cell mediated immunity and suppressor T cell function in children with cystic fibrosis. Lung 157 (4): 219–228

    PubMed  CAS  Google Scholar 

  31. Hiatt P, Eigen H, Yu P, Tepper RS (1988) Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis 137:119–12

    PubMed  CAS  Google Scholar 

  32. Hiatt P (1992) The role of viral infections in cystic fibrosis. Pediatr Pulmonol Suppl 8:18–19

    Google Scholar 

  33. Katz JN, Horowitz RI, Dolan TF, Shapiro ED. (1986) Clinical features as predictor of functional Status in children with cystic fibrosis. J Pediatr 108:352–35

    PubMed  CAS  Google Scholar 

  34. Katznelson D, Szeinberg A, Augarten A, Yahav Y (1997) The critical first six months in cystic fibrosis: A Syndrome of severe bronchiolitis. Pediatr Pulmonol 24:134–136

    PubMed  CAS  Google Scholar 

  35. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am Respir Crit Care Med 151:1075–1082

    CAS  Google Scholar 

  36. Knutsen AP, Slavin RG, Roodman ST et al. (1988) Decreased T helper cell function in patients with cystic fibrosis. Int Arch Allergy Appl Immunol 85 (2): 208–212

    PubMed  CAS  Google Scholar 

  37. Konstan MW, Berger M (1997) Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology. Pediatr Pulmonol 24:137–142

    PubMed  CAS  Google Scholar 

  38. Lahat N, Rivlin J, Iancu TC (1989) Functional immunoregulatory T cell abnormalities in cystic fibrosis patients. J Clin Immunol 9 (4): 287–295

    PubMed  CAS  Google Scholar 

  39. Lloyd-Still JD, Khan KT, Shwachmann H (1974) Severe respiratory disease in infants with cystic fibrosis. Pediatrics 53:678–682

    PubMed  CAS  Google Scholar 

  40. Massion PP, Inoue H, Richman-Eisenstat J et al. (1994) Novel Pseudomonas produet stimulates interleukin-8 production in airway epithelial cells in vitro. J Clin Invest 93(1):T26–T32

    Google Scholar 

  41. May TB, Shinabarger D, Maharaj R et al. (1991) Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 4 (2):191–206

    PubMed  CAS  Google Scholar 

  42. McElvany NG, Nakamura H, Birrer P et al. (1992) Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithel surface by aerosolisation of recombinant secretory leucoprotease inhibitor. J Clin Invest 90 (4): 1296–1301

    Google Scholar 

  43. Meluleni GJ, Grout M, Evans DJ et al. (1995) Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 155:2029–2038

    PubMed  CAS  Google Scholar 

  44. Mizgerd JP, Kobzik L, Warner AE et al. (1995) Effects of sodium concentration on human neutrophil bactericidal functions. Am J Physiol 269 (Lung Cell Mol Physiol): L388–L393

    PubMed  CAS  Google Scholar 

  45. Moore KW, O’Garra A, de Waal Malefyt R et al. (1993) Interleukin-10. Annu Rev Immunol 11:165–190

    PubMed  CAS  Google Scholar 

  46. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McKoy K, McNamara S, Ramsey B, Wagener J (1999) Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 28:321–328

    PubMed  CAS  Google Scholar 

  47. Saiman L, Cacalano G, Gruenert D et al. (1992) Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect Immunol 60 (7): 2808–2814

    CAS  Google Scholar 

  48. Saiman L, Prince A (1993) Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 92 (4):1875–1880

    PubMed  CAS  Google Scholar 

  49. Santos JI, Hill HR (1984) Neutrophil function in cystic fibrosis. In: Shapira E, Wilson GB (eds) Immunological aspects of cystic fibrosis. CRC Press, Boca Raton, pp 29–37

    Google Scholar 

  50. Smith JJ, Travis SM, Greenberg EP et al. (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229–236

    PubMed  CAS  Google Scholar 

  51. Sorensen RU, Waller RL, Klimger JD (1990) Cystic fibrosis. Infection and immunity to Pseudomonas. Clin Rev Allergy 9:47–74

    Google Scholar 

  52. Stern RC, Boat TF, Wood RE, Matthews LW, Doershuk CF (1982) Treatment and prognosis of nasal polyps in cystic fibrosis. Am J Dis Child 126:1067–1070

    Google Scholar 

  53. Sturgess J, Imrie J (1982) Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 106:303–311

    PubMed  CAS  Google Scholar 

  54. Sturgess J (1982) Morphologic characteristics of the bronchial mucosa in cystic fibrosis. In: Quinton P, Martinez R, Hopfer U (eds) Fluid and electrolyte abnormalities in exocrine glands in cystic fibrosis. San Francisco Press, San Francisco, p 254

    Google Scholar 

  55. Tomashefski JF, Bruce M, Golgberg HI, Dearborn DG (1986) Regional distribution of macroscopic lung disease in cystic fibrosis. Am Rev Respir Dis 133:535–540

    PubMed  Google Scholar 

  56. Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320 (6):365–376

    PubMed  CAS  Google Scholar 

  57. Wiatrik BJ, Myer CM, Cotton RT (1993) Cystic fibrosis presenting with sinus disease in children. Am J Dis Child 147:258

    Google Scholar 

  58. Wood RE, Boat TF, Dorshuk CF (1976) Cystic fibrosis. Am Rev Respir Dis 113:833–878

    PubMed  CAS  Google Scholar 

Liteatur zu 7.3.1

  1. Ballmann M, Rabsch P, von der Hardt H (1998) Long term follow up of changes of FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 53:732–737

    PubMed  CAS  Google Scholar 

  2. Bargon J, Dauletbaev N, Kohler B, Wolf M, Posselt HG, Wagner TO (1999) Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 93:835–838

    PubMed  CAS  Google Scholar 

  3. Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, Barson WJ (1997) Pharmakokinetics and safety of tobramyein after once-daily administration in patients with cystic fibrosis. Chest 112:1208–1213

    PubMed  CAS  Google Scholar 

  4. Beardsmore CS, Thompson JR, Williams A, McArdle EK, Gregory GA, Weaver LT, Simpson H (1994) Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 71:133–137

    PubMed  CAS  Google Scholar 

  5. Bosworth DG, Nielson DW (1997) Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 24:42–47

    PubMed  CAS  Google Scholar 

  6. Burns J, Saiman L (1999) Burkholderia cepacia infections in cystic fibrosis. Pediatr Infect Dis J18:155–156

    Google Scholar 

  7. Campbell PW 3, Saiman L (1999) Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 116:775–788

    PubMed  CAS  Google Scholar 

  8. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, Le Souef PN (1994) The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 7: 2185–2191

    PubMed  CAS  Google Scholar 

  9. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R (1991) Safety of Ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on Joint evaluation. Infection 19:289–296

    PubMed  CAS  Google Scholar 

  10. Ciofu O, Jensen T, Pressler T, Johansen HK, Koch C, Hiby N (1996) Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics. Clin Microbiol Infect 2:91–98

    PubMed  CAS  Google Scholar 

  11. Cystic Fibrosis Foundation (1998) Patient Registry 1997 Annual Data Report, Bethesda, Maryland, Sept 1998

    Google Scholar 

  12. Davis P, Drumm M, Konstan MI (1996) Cystic fibrosis: State of the art. Am J Respir Crit Care Med 154:1229–1256

    PubMed  CAS  Google Scholar 

  13. Editorial (1985) Antibiotic dosage in cystic fibrosis. Lancet 1:1020–1021

    Google Scholar 

  14. Ernst RK, Yi EC, Guo L, Lim KB, Burns JL, Hackett M, Miller SI (1999) Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286:1561–1565

    PubMed  CAS  Google Scholar 

  15. Frederiksen B, Lanng S, Koch C, Høiby N (1996) Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 21:153–158

    PubMed  CAS  Google Scholar 

  16. Frederiksen B, Koch C, Hoiby N (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23:330–335

    PubMed  CAS  Google Scholar 

  17. Götz M (1985) Pulmonale Infektionen bei cystischer Fibrose: Pathogenese und Therapie. Monatsschr Kinderheilkd 133: 718–725

    PubMed  Google Scholar 

  18. Jaffe A, Francis J, Rosenthal M, Bush A (1998) Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351:420

    PubMed  CAS  Google Scholar 

  19. KeremE,CoreyM,RoldRetal.(1990) Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116:714–719

    Google Scholar 

  20. Konstan M, Butler SM, Schidlow DV, Morgan WJ, Julius RJ, Johnson CA (1999) Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Pediatr Pulmonol 28: 248–254

    PubMed  CAS  Google Scholar 

  21. Le Brun PP, de Boer AH, Gjaltema D, Hagedoorn P, Heijerman HG, Frijlink HW (1999) Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin Solution for a jet and an ultrasonic nebulizer. Int J Pharm 189: 215–225

    Google Scholar 

  22. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ (1998) Four years’ experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 12592–594

    Google Scholar 

  23. Mallol J, Rattray S, Walker G, Cook D, Robertson CF (1996) Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 21:276–281

    PubMed  CAS  Google Scholar 

  24. McCaffery K, Olver RE, Franklin M, Mukhopadhyay (1999) Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax 54:380–383

    PubMed  CAS  Google Scholar 

  25. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F (1994) The quantitative distribution of nebulized antibiotics in the lung in cystic fibrosis. Respir Med 88:203–211

    PubMed  CAS  Google Scholar 

  26. Mukhopadhyay S, Singh M, Cater JL, Ogston S, Franklin M, Olver RE (1996) Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a metaanalysis of benefits and risks. Thorax 51:364–368

    PubMed  CAS  Google Scholar 

  27. Qualitätssicherung Mukoviszidose (1998) Überblick über den Gesundheitszustand der Patienten in Deutschland 1997. Zentrum für Qualitätsmanagement im Gesundheitswesen, Hannover

    Google Scholar 

  28. Ramsey (1996) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335:179–188

    PubMed  CAS  Google Scholar 

  29. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman DM, Marshall BC, Marshall S, Smith AL. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340:23–30

    PubMed  CAS  Google Scholar 

  30. Ring E, Eber E, Erwa W, Zach MS (1998) Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation. Arch Dis Child 78:540–543

    PubMed  CAS  Google Scholar 

  31. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A (1996) Antibiotic susceptibility of multiply resistant Pseudomnas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23:532–537

    PubMed  CAS  Google Scholar 

  32. Saiman L (1998) Use of aerosolized antibiotics in patients with cystic fibrosis. Pediatr Infect Dis J17:158–159

    Google Scholar 

  33. Sakata K, Yajima H, Tanaka K, Sakamoto Y, Yamamoto K, Yoshida A, Dohi Y (1993) Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting the proliferation in vitro. Am Rev Respir Dis 148: 1061–1065

    PubMed  CAS  Google Scholar 

  34. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P (1991) Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of Ciprofloxacin. Pediatr Infect Dis J10:723–729

    PubMed  CAS  Google Scholar 

  35. Schaad UB, Abdus Salam M, Aujard Y, Dagan R, Green SD, Peltola H, Rubio TT, Smith AL, Adam D(1995) Use of fluoroquinolones in pediatrics: a consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 14:1–9

    Google Scholar 

  36. Schwab U, Gilligan P, Jaynes J, Henke D (1999) In vitro activities of designed antimicrobial peptides against multi-drug-resistant cystic fibrosis pathogens. Antimicrob Agents Chemother 43:1435–1440

    PubMed  CAS  Google Scholar 

  37. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, Tanaka SK (1999) Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 43:2877–2880

    PubMed  CAS  Google Scholar 

  38. Steinkamp G, Tümmler B, Gappa M, Albus A, Potel J, Döring G, von der Hardt H (1989) Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 6:91–98

    PubMed  CAS  Google Scholar 

  39. Thomas SR, Gyi KM, Gaya H, Hodson ME (1998) Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect 40:203–209

    PubMed  Google Scholar 

  40. Valerius NH, Koch C, Høiby N (191) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. 338:725–726

    Google Scholar 

  41. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, Sardet A, Deschildre A, Druon D, Arrouet-Lagande C (19998) Efficacy, tolerance and pharmakokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 78:536–539

    Google Scholar 

  42. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, Austin S, Gregory GA, Dux AEW, Davis JA (1994) Prognosis of cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 70: 84–89

    PubMed  CAS  Google Scholar 

  43. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, Hardt Hvd (1998) Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25:88–92

    PubMed  CAS  Google Scholar 

  44. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E (2000) A pilot study of the effect of gantamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860–865

    PubMed  CAS  Google Scholar 

  45. Wilson D, Burniston M, Moya E, Parkin A, Smye R, Robinson P, Littlewood J (1999) Improvement of nebulised antibiotic delivery in cystic fibrosis. Arch Dis Child 80: 348–352

    PubMed  CAS  Google Scholar 

Liteatur zu 7.3.2

  1. Aronoff SC, Quinn FJ, Carpenter LS, Novick WJ (1994) Effects of pentoxifylline on Sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: Preliminary observations. J Pediatr 125: 992–997

    PubMed  CAS  Google Scholar 

  2. Auerbach HS, Williams M, Kirkpatrick JA, Cohen HR (1985) Alternate-day prednisone reduces morbitity and improves pulmonary function in cystic fibrosis. Lancet 2: 686–688

    PubMed  CAS  Google Scholar 

  3. Balfour-Lynn IM, Klein NJ, Dinwiddie R (1997) Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 77: 124–130

    PubMed  CAS  Google Scholar 

  4. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Doring G (1989) Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 84:1302–1313

    PubMed  CAS  Google Scholar 

  5. Dauletbaev N, Viel K, Behr J, Loitsch S, Buhl R, Wagner TOF, Bargon J (1999) Effects of short-term inhaled fluticasone on oxidative burst of Sputum cells in cystic fibrosis. Eur Respir J 14:1150–1155

    PubMed  CAS  Google Scholar 

  6. Eigen H, Rosenstein BJ, Fitzsimmons S, Schidlow D (1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 126:515–523

    PubMed  CAS  Google Scholar 

  7. Keicher U, Koletzko B, Reinhardt D (1995) Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur J Clin Invest 25:915–919

    PubMed  CAS  Google Scholar 

  8. Konstan MW, Byard PJ, Hoppel CL, Davis PB (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332:848–854

    PubMed  CAS  Google Scholar 

  9. Konstan MW, Hoppel CL, Chai B, Davis PB (1991) Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 118:956–964

    PubMed  CAS  Google Scholar 

  10. Konstan MW, Vargo KM, Davis PB (1990) Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis 141:186–192

    PubMed  CAS  Google Scholar 

  11. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB (1993) Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 148:896–901

    PubMed  CAS  Google Scholar 

  12. Lawrence R, Sorrell T (1993) Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 342:465–469

    PubMed  CAS  Google Scholar 

  13. Matthews WJ, Williams M, Oliphant B, Geha R, Colten HR (1980) Hypogammaglobulinemia in cystic fibrosis. N Engl J Med 302:245–249

    PubMed  Google Scholar 

  14. Zinman R, Corey M, Coates AL, Canny GJ, Connoly J, Levison H, Beaudry PH (1989) Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. J Pediatr 114:368–377

    PubMed  CAS  Google Scholar 

  15. Nikolaiczik WH, Schöni MH (1996) Pilot study to assess the effects of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 128:271–274

    Google Scholar 

  16. Rosenstein BJ, Eigen H (1991) Risks of alternate-day Prednisone in patients with cystic fibrosis. J Pediatr 87: 245–246

    CAS  Google Scholar 

  17. Schiotz PO, Jorgensen M, Flensburg EW et al. (1983) Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Acta Paediatr Scand 72:283–287

    PubMed  CAS  Google Scholar 

  18. Schmidt J, Davidson AGF, Seear M, Wong LTK, Peacock D, Gravelle A, Menon K, Cimolai N, Speert DP (1997) Is the acquisition of Pseudomonas in cystic fibrosis patients in-creased by use of inhaled corticosteroids? Unexpected results from a double blind placebo controlled study. Pediatr Pulmonol Suppl 14:318A

    Google Scholar 

  19. Wedzicha JA (2000) Long-term oxygen therapy. Eur Respir Mon 13:143–154

    Google Scholar 

  20. Tüxen-Mengedoht M, Koletzko B, Müller I, Demmelmair H, Knapp V, Stern M, Steffan J, Lietz TA, Henker J, Brömme S, Franz R, Wille L, Mayatepek E, Wolf A, Reinhardt D (1999) Fischöl-Therapie bei CF: Eine randomisierte Doppelblindstudie. Monatsschr Kinderheilkd 147 (Suppl 2): S107

    Google Scholar 

  21. Van Haren EHJ, Lammers JWJ, Festen J, Heijerman HGM, Groot CAR, van Heerwarden CLA (1995) The effects of the inhaled contricosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 89:209–214

    PubMed  Google Scholar 

  22. Wheeler WR, Williams Matthews WJ, Colten HR (1984) Progression of cystic fibrosis lung disease as a function of serum Immunoglobulin G levels: a five year longitudinal study. J Pediatr 184:695–699

    Google Scholar 

Liteatur zu 7.3.3

  1. Bargon J, Viel K, Dauletbaev N, Wiewrodt R, Buhl R (1999) Short term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Respir J10 (10):2307–2311

    Google Scholar 

  2. Becker AB, Simons FER (1989) Formoterol, a new long-acting inhaled β2-agonist: double blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 84:891–895

    PubMed  CAS  Google Scholar 

  3. Berdel D, Reinhardt D, Hofmann D, Leupold W, Lindemann H (1998) Therapieempfehlungen der Gesellschaft für Pädiatrische Pneumologie zur Behandlung des Asthma bronchiale bei Kindern und Jugendlichen. Monatsschr Kinderheilkd 146:492–497

    Google Scholar 

  4. Berg A von, Berdel D (1989) Formoterol and salbutamol metered aerosols: comparison of a new and an established β2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma. Pediatr Pulmonol 7:89–93

    Google Scholar 

  5. Cook SJ, Small RC, Berry JL, Chiu P, Downing SJ, Foster RW (1993) β-adrenoceptor Subtypes and the opening of plas-malemmal K+-channels in trachealis muscle: electrophysiological and mechanical studies in guinea-pig tissue. Br J Pharmacol 109:1140–1148

    PubMed  CAS  Google Scholar 

  6. Cropp GJ (1996) Effectiveness of bronchodilators in cystic fibrosis. Am J Med 100 (1A): 19S–29S

    PubMed  CAS  Google Scholar 

  7. Daniel EE, Grover AK, Kwan CY (1983) Calcium. In: Stephens NL (ed) Biochemistry of smooth muscle, vol III. CRC Press, Boca Raton, p 2

    Google Scholar 

  8. Dowling RB, Rayner CFJ, Rutman A, Jackson AD, Khanthakumar K, Dewar A, Taylor GW, Cole PJ, Johnson M, Wilson R (1997) Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care 155: 327–336

    CAS  Google Scholar 

  9. Eber E, Oberwaldner B, Zach MS (1988) Airway obstruction and airway instability in cystic fibrosis: the isolated and combined effect of Theophylline and sympathomimetics. Pediatr Pulmonol 4:205–212

    PubMed  CAS  Google Scholar 

  10. Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner ScD and RA (1991) A controlled trial of long-term bronchodilator therapy in Cystic Fibrosis. Chest 99:1088–1092

    PubMed  CAS  Google Scholar 

  11. Fuglsang G, Vikre-Jorgensen J, Agertoft L, Pedersen S (1998) Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr Pulmonol 25:314–321

    PubMed  CAS  Google Scholar 

  12. Gebbie T (1983) Therapeutic choices in asthma. In: Clark TJH (ed) Steroids in asthma. Adis, Auckland New York London, p 83

    Google Scholar 

  13. Hordvik NL, Sammut PH, Judy CG, Colombo JL (1999) Effects of Standard and high doses of salmeterol on the lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol 27 (1) 43–53

    PubMed  CAS  Google Scholar 

  14. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL (1996) The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 154 (1)156–160

    PubMed  CAS  Google Scholar 

  15. Källström BL, Sjöberg J, Waldeck B (1994) The interaction between salmeterol and β2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 113:687–692

    PubMed  Google Scholar 

  16. Kattan M, Mansell A, Levison H, Corey M, Krastins IRB (1980) Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis. Thorax 35:531–535

    PubMed  CAS  Google Scholar 

  17. Kerrick WGL, Hoar PE (1981) Inhibition of smooth muscle tension by cyclic AMP-dependent protein kinase. Nature 292:253

    PubMed  CAS  Google Scholar 

  18. Kraemer R, Birrer P, Modelska K, Casaulta Aebischer C, Schöni MH (1992) A new baby-spacer device for aerosolized bronchodilator administration in infants with broncho-pulmonary disease. Eur J Pediatr 151:57–60

    PubMed  CAS  Google Scholar 

  19. König P, Poehler J, Barbero G (1998) A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol 25:32–37

    PubMed  Google Scholar 

  20. Kusenbach G, Friedrichs F, Skopnik H, Heimann G (1993) Increased physiological dead space during exercise after bronchodilation in cystic fibrosis. Pediatr Pulmonol 15 (5): 273–278

    PubMed  CAS  Google Scholar 

  21. Lemoine H, Reinhardt D (1999) Nervöse und neurohumorale Einflüsse. In: Reinhardt D (Hrsg) Asthma bronchiale im Kindesalter. Springer, Berlin Heidelberg New York Tokio, S 63–84

    Google Scholar 

  22. Lenney W, Pedersen S, Boner AL, Ebbut A, Jenkins MM (1995) Efficacy and safety of salmeterol in childhood asthma. Eur J Pediatr 154:983–990

    PubMed  CAS  Google Scholar 

  23. Li X, Ward Ch, Thien F, Bish R, Bamford T, Bao X, Bailey M, Wilson JW, Walters EH (1999) An antiinflammatory effect of Salmeterol, a long-acting β2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160:1493–1499

    PubMed  CAS  Google Scholar 

  24. Molimard M, Naline E, Zhang Y, Le Gros V, Begaud B, Advenier C (1998) Long- and short-acting β2-adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 11:583–588

    PubMed  CAS  Google Scholar 

  25. Rabe KF, Chung KF (1991) The challange of long-acting β-adrenocepter agonists. Respir Med 85:5–9

    PubMed  CAS  Google Scholar 

  26. Sanchez I, de Koster J, Holbrow J, Chernick V (1993) The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest 104 (3): 842–846

    PubMed  CAS  Google Scholar 

  27. Scheid CR, Honeyman TW, Fay FS (1979) Mechanism of β-adrenergic relaxation of smooth muscle. Nature 277:32–36

    PubMed  CAS  Google Scholar 

  28. Shapiro GG, Bamman J, Kanarek P, Biermann CW (1976) The paradoxical effect of adrenergic and methylxanthine drugs in cystic fibrosis. Pediatrics 58:740–742

    PubMed  CAS  Google Scholar 

  29. Sparrow MP, Pfitzer M, Gagelmann M, Rüegg JC (1984) Effect of calmodulin, Ca2+ and cAMP protein kinase on skinned tracheal smooth muscle. Am J Physiol 246:C308

    PubMed  CAS  Google Scholar 

  30. Teschemacher A, Lemoine H (1999) Kinetic analysis of drug-receptor interactions of long acting β2-sympathomimetics in isolated receptor membranes. Evidence against prolonged effects of salmeterol and formoterol on receptor coupled adenyl cyclase. J Pharmacol Exp Ther 288: 1084–1092

    PubMed  CAS  Google Scholar 

  31. Waldeck B (1996) Some pharmacodynamic aspects on long-acting β-adrenoceptor agonists. Gen Pharmacol 27 (4): 575–580

    PubMed  CAS  Google Scholar 

  32. Wettengel R, Berdel D, Krause J et al. (1999) Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie 52:591–601

    Google Scholar 

  33. Wiewrodt R, Kim W, Viel K, Caspary W, Buhl R, Bargon J (1996) Broncholytic effect of β2-agonists in adult patients with cystic fibrosis. Allergy 51 (Suppl 30): 79

    Google Scholar 

  34. Wood RE, Wanner A, Hirsch J, Farrell PM (1975) Tracheal mucociliary transport in patients with cystic fibrosis and its Stimulation by terbutaline. Am Rev Respir Dis 111 (6): 733–738

    PubMed  CAS  Google Scholar 

  35. Zach MS, Oberwaldner B, Forche G, Polgar G (1985) Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 131:537–543

    PubMed  CAS  Google Scholar 

  36. Zach MS (1990) Lung disease in cystic fibrosis — an update concept. Pediatr Pulmonol 8:188–200

    PubMed  CAS  Google Scholar 

  37. Zapletal A, Motoyama EK, Gibson LE, Bouhuys A (1971) Pulmonary mechanics in asthma and cystic fibrosis. Pediatrics48:64–72

    Google Scholar 

Liteatur zu 7.3.4

  1. Anzueto A, Jubran A, Ohar JA, Pipuette C, Rennard S (1997) Effects of aerosolized Surfactant in patient with stable chronic bronchitis. JAMA 278:1426–1431

    PubMed  CAS  Google Scholar 

  2. Baran D (1980) Klinischer Doppelblindversuch mit oralem Actetylcystein und Placebo bei zystischer Fibrose. Therapiewoche 30:2034–2039

    Google Scholar 

  3. Bentzmann d, Pierrot D, Fuchey C, Zahm JM, Morancais JL, Puchelle E (1993) Distearoyl phosphatidylglycerol Liposomes improve surface and transport properties of CF mucus. Eur Respir J 6:1156–1161

    Google Scholar 

  4. Canny GJ (1996) Hypertonie saline in cystic fibrosis. Pediatr Pulmonol 21:73–74

    PubMed  CAS  Google Scholar 

  5. Davoodian K, Ritchings B, Ramphai R, Bubb M (1997) Gelsolin activates DNase I in vitro and in cystic fibrosis Sputum. Biochemistry 36:9637–9641

    PubMed  CAS  Google Scholar 

  6. Dietzsch H-J, Gottschalk B, Heyne K, Leupold W, Wunderlich P (1975) Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetyleysteine and arginine hydrochloride). Pediatrics 55:96–100

    PubMed  CAS  Google Scholar 

  7. Duijvestijn YCM, Brand PLP (1999) Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr 88:38–41

    PubMed  CAS  Google Scholar 

  8. Eng P, Morton J, Douglass J, Riedler J, Wilson J, Robertson C (1996) Short-term effkaey of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 21:77–83

    PubMed  CAS  Google Scholar 

  9. Ghio AJ, Marshall B, Diaz J, Hasegawa T, Samuelson W, Povia D, Kennedy T, Piantadosi C (1996) Tyloxapol inhibits NF-KB and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis Sputum. Am J Respir Crit Care Med 154:783–788

    PubMed  CAS  Google Scholar 

  10. Götz M, Kraemer R, Kerrebijn K, Popow C (1980) Oral acetylcysteine in cystic fibrosis a cooperative study. Eur J Respir Dis 61:122–126

    Google Scholar 

  11. Griese M, App EM, Duroux A, Burkert A, Schams A (1997) Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis Sputum. Pulm Pharmacol Ther 10:21–27

    PubMed  CAS  Google Scholar 

  12. Griese M, Butler P, Teller J, Reinhardt D (1997) Nebulization of a bovine Surfactant in cystic fibrosis: a pilot study. Eur Respir J 10:1989–1997

    PubMed  CAS  Google Scholar 

  13. Howatt WF, DeMuth G (1966) A double-blind study of the use of acetylcysteine in patients with cystic fibrosis. Univ Mich Med Centr J 32:82–85

    CAS  Google Scholar 

  14. Koch C, McKenzie S, Kaplowitz, Hodson M, Harms H, Navarrow J, Mastella G (1997) International practice patterns by age and severity of lung disease in cystic fibrosis: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 24:147–154

    PubMed  CAS  Google Scholar 

  15. Lawson D, Saggers BA (1965) NAC and antibiotics in cystic fibrosis. Br Med J 1:317–317

    PubMed  CAS  Google Scholar 

  16. Mitchell E, Elliot R (1982) Controlled trial of oral Nacetylcysteine in cystic fibrosis. Aust Paediatr J 18:40–42

    PubMed  CAS  Google Scholar 

  17. Pattishall EN (1990) Negative clinical trials in cystic fibrosis. Pediatrics 85:277–281

    PubMed  CAS  Google Scholar 

  18. Rao S, Wilson DB, Brooks RC, Sproule BJ (1970) Acute effects of nebulization of Nacetylcysteine on pulmonary mechanics and gas exchange. Am Rev Respir Dis 102: 17–25

    PubMed  CAS  Google Scholar 

  19. Ratjen F, Wönne R, Posselt H-G, Stöver B, Hofmann D, Bender S (1985) A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytie treatment in cystic fibrosis. Eur J Pediatr 144:374–378

    PubMed  CAS  Google Scholar 

  20. Rodwell L, Anderson S (1994) Hyperosmolar aerosol challenge: a useful tool in the mangement of subjects with cystic fibrosis. Aust N Z J Med 24:484

    Google Scholar 

  21. Romano C, Gargani G, Minicucci L, Nantron M (1984) Clinico contollato sull’atività di un nuovo farmaco mucoregolatore nella patologia astruttiva bronchiale a marcata improta ipersecretiva. Minerva Pediatr 36:127–138

    PubMed  CAS  Google Scholar 

  22. Stafanger G, Garne S, Howitz P, Morkassel E, Koch C (1988) The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J1:161–167

    Google Scholar 

  23. Stephan U, Böwing B, Goering U, Wiesemann H, Reinhardt M, Hirche H, Brandt H (1980) Acetyleysteine in the oral mucolytie treatment of cystic fibrosis. Eur J Respir Dis 61:127–131

    Google Scholar 

  24. Stern RC (1998) Inpatient treatment of cystic fibrosis pulmonary disease. In: Orenstein D, Stern RC (eds)  Treatment of the hospitalized cystic fibrosis patient. Dekker, New York, pp 79–133

    Google Scholar 

  25. Tecklin J, Holsclaw D (1976) Bronchial drainage with aerosol medications in cystic fibrosis. Phys Ther 56:999–1003

    PubMed  CAS  Google Scholar 

  26. Waring WW (1976) Current management of cystic fibrosis. Adv Pediatr 23:401–438

    PubMed  CAS  Google Scholar 

  27. Weller P, Ingram D, Preece M, Matthew D (1980) Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax 35:42–46

    PubMed  CAS  Google Scholar 

Liteatur zu 7.3.5

  1. Aitken M, Burke W, McDonald G, Shak S, Montgomery A, Smith A (1992) Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 267:1947–1951

    PubMed  CAS  Google Scholar 

  2. Armstrong J, White J (1950) Liquefaction of viscous purulent exsudes by deoxyribonuclease. Lancet 739–742

    Google Scholar 

  3. Barton D, Ryder K, Lourenco R, Dralle W, Weiss S (1976) Inflammatory reaction and airway damage in cystic fibrosis. J Lab Clin Med 88:423–426

    PubMed  CAS  Google Scholar 

  4. Böllert F, Paton J, Marshall T, Calvert J, Greening A, Innes J (1999) Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Eur Respir J13:107–113

    Google Scholar 

  5. Cantin A (1998) DNase I acutely increases cystic fibrosis Sputum elastase activity and its potential to induce lung hemorrhage in mice. Am J Respir Crit Care Med 157:464–469

    PubMed  CAS  Google Scholar 

  6. Cipolla D, Clark A, Chan H-K, Gonda I, Shire S (1994) Assessment of aerosol delivery Systems for recombinant human deoxyribonuclease. S T P Pharma Sciences 4:50–62

    Google Scholar 

  7. Costello C, O’Connor C, Finlay G, Shiels P, FitzGerald M, Hayes J (1996) Effect of nebulized recombinat DNase on neutrophil elastase load in cystic fibrosis. Thorax 51:619–623

    PubMed  CAS  Google Scholar 

  8. Cramer G, Bosso J (1996) The role of dornase alpha in the treatment of cystic fibrosis. Ann Pharmacother 30:656–661

    PubMed  CAS  Google Scholar 

  9. Dasgupta B, King M (1996) Reduction in viscoelasticity in cystic fibrosis Sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol 22:161–166

    PubMed  CAS  Google Scholar 

  10. Dasgupta B, Tomkiewicz RP, Boyd WA, Brown NE, King M (1995) Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis Sputum in vitro. Pediatr Pulmonol 20:78–82

    PubMed  CAS  Google Scholar 

  11. Davies J, Trindade M-T, Wallis C, Rosenthal M, Crawford O, Bush A (1997) Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 23: 243–24

    PubMed  CAS  Google Scholar 

  12. Davoodian K, Ritchings B, Ramphai R, Bubb M (1997) Gelsolin activates DNase I in vitro and in cystic fibrosis Sputum. Biochemistry 36:9637–9641

    PubMed  CAS  Google Scholar 

  13. Fiel S, Fuchs H, Johnson C, Gonda I, Clark A (1995) Comparison of three jet nebulizer aerosol delivery Systems used to administer recombinant human DNase I to patients with cystic fibrosis. Chest 108:153–156

    PubMed  CAS  Google Scholar 

  14. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory Symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331:637–642

    PubMed  CAS  Google Scholar 

  15. Geller D, Eigen H, Fiel S, Clark A, Lamarra A, Johnson C, Konstan M (1998) Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol 25:83–87

    PubMed  CAS  Google Scholar 

  16. Griese M, App EM, Duroux A, Burkert A, Schams A (1997) Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis Sputum. Pulm Pharmacol Ther 10:21–27

    PubMed  CAS  Google Scholar 

  17. Hodson M, Shah P (1995) DNase trials in cystic fibrosis. Eur Respir J 8:1786–1791

    PubMed  CAS  Google Scholar 

  18. Hubbard RC, McElvaney N, Birrer P, Shak S, Robinson W, Jolley C, Wu M, Chernick M, Crystal RG (1992) A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 326:812–815

    PubMed  CAS  Google Scholar 

  19. King M, Dasgupta B, Tomkiewicz RP, Brown NE (1997) Rheology of cystic fibrosis Sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 156:173–177

    PubMed  CAS  Google Scholar 

  20. Kirchner K, Wagener J, Khan T, Copenhaver S, Accurso F (1996) Increased DNA levels in bronchoalverolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 154:1426–1429

    PubMed  CAS  Google Scholar 

  21. Kling S, Gie R, Riphagen S (1997) Dornase alpha in the management of mechanically ventilated infant with cystic fibrosis. Pediatr Pulmonol 23:124–125

    Google Scholar 

  22. Ledson M, Wahbi Z, Convery R, Cowperthwaite C, Heaf D, Walshaw M (1998) Targeting of dornase alpha therapy in adult cystic fibrosis. J R Soc Med 91:360–364

    PubMed  CAS  Google Scholar 

  23. Lieberman J (1967) Inhibition of protease activity in purulent Sputum by DNA. J Lab Clin Med 70:595–605

    PubMed  CAS  Google Scholar 

  24. McCoy K, Hamilton S, Johnson C (1996) Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 110:889–895

    PubMed  CAS  Google Scholar 

  25. Ramsey BW, Astley S, Aitken M, Burke W, Colin A, Dorkin H, Eisenberg J, Gibson R, Harwood I, Schidlow D, Wilmott R, Wohl ME, Meyerson L, Shak S, Fuchs H, Smith AL (1993) Efficacy and safety of short-term adminstration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 148:145–151

    PubMed  CAS  Google Scholar 

  26. Ramsey BW, Dorkin H (1994) Consensus Conference: practical applications of Pulmozyme. Pediatr Pulmonol 17:404–408

    PubMed  CAS  Google Scholar 

  27. Rochat T, Pastore F, Schlegel-Haueter S, Filthuth I, Auckenthaler R, Belli D, Suter S (1996) Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum. Eur Respir J 9:2200–2206

    PubMed  CAS  Google Scholar 

  28. Shah P, Bush A, Canny G, Colin A, Fuchs HJ, Geddes D, Johnson C, Light M, Scott S, Tullis D, DeVault A, Wohl ME, Hodson M (1995) Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 8:954–958

    PubMed  CAS  Google Scholar 

  29. Shah P, Scott S, Geddes D, Hodson M (1995) Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 89:499–502

    PubMed  CAS  Google Scholar 

  30. Shah P, Scott S, Knight R, Hodson M (1996) The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the Sputum of patients with cystic fibrosis. Eur Respir J 9:531–534

    PubMed  CAS  Google Scholar 

  31. Touleimat B, Conoscenti C, Fine J (1995) Recombinant human DNase in management of lobar atelectasis due to retained secretions. Thorax 50:1319–1321

    PubMed  CAS  Google Scholar 

  32. Wagener J, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC, for the Pulmozyme pediatric bronchoscopy study group (1998) Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. J Pediatr 133:486–491

    PubMed  CAS  Google Scholar 

  33. Wilmott R, Amin R, Colin A, DeVault A, Dozor A, Eigen H, Johnson C, Lester L, McCoy K, McKean L, Moss R, Nash ML, Pagel Jue C, Regelmann W, Stokes D, Fuchs HJ (1996) Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 153:1914–1917

    PubMed  CAS  Google Scholar 

  34. Ying Q-L, Simon SR (1995) Accelerated binding of secretory leukoprotease inhibitor to human leukocyte elastase mediated by single-stranded sites in DNA from trachea-bronchial mucus. Am J Respir Cell Mol Biol 13:701–711

    Google Scholar 

Liteatur zu 7.3.6

  1. Anderson WH (1993) Pharmacokinetics of amiloride by inhalation in adults, adolescents, and children. 19th Cystic Fibrosis Conference. Madrid, Spain, May 21–26

    Google Scholar 

  2. App EM (1996) Vergleichende Mukolytikatherapie. Pneumologie 50:845–853

    PubMed  Google Scholar 

  3. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR. (1996) Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 153:1796–1801

    PubMed  CAS  Google Scholar 

  4. Blank U, Clauss W, Weber WM (1995) Effects of benzamil in human cystic fibrosis airway epithelium. Cell Physiol Biochem 5:385–390

    CAS  Google Scholar 

  5. Boucher RC, Stutts MJ, Knowles MR, Cantley L, Gatzy JT (1986) Na+ transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclase activitation. J Clin Invest 78:1245–1252

    PubMed  CAS  Google Scholar 

  6. Boucher RC (1994) Human airway ion transport (part 1,2). Am J Respir Crit Care Med 150:271–281; 581–593

    PubMed  CAS  Google Scholar 

  7. Boucher RC, Olivier K, Bennett W, Hohnecker K, Geary C, Davis CW, Knowles MR (1995) Aerosolized uridine triphosphate (UTP) and amiloride: Safety and effects in normal subjects and CF patients. J Aerosol Med 8:S30

    Google Scholar 

  8. Bowler IM, Kelman B, Worthington D, Littlewood JM, Watson A, Conway SP, Smye SW, James SL, Sheldon TA (1995) Nebulized amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 73:427–430

    PubMed  CAS  Google Scholar 

  9. Brown HA, Lazarowski ER, Boucher RC, Harden TK (1991) Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5′-nucleotide receptor in human airway epithelial cells. Mol Pharmacol 40:648–655

    PubMed  CAS  Google Scholar 

  10. Church NL, Burroughs SM, Wisniewski ME, Anderson WH, AML302/303 (1996) Clinical investigators. The effect of amiloride on the decline of pulmonary function in cystic fibrosis patients 10 years of age and older. Pediatr Pulmonol Suppl 13:279–280 (abstract)

    Google Scholar 

  11. Cutting GR (1998) CLC-2 Channels and CF. Pediatric Pulmonology Suppl 17:123–124

    Google Scholar 

  12. Donaldson SH, Boucher RC, Knowles MR (1996) In vivo regulation of ATP levels in human nasal epithelia. Pediatr Pulmonol Suppl 13:289 (abstract)

    Google Scholar 

  13. Dougherty RW, Croom DK, James MK, Jones AC, Pendergast W, Yerxa BR, Abraham WM, Sabater JR, Davis CW, Stutts MJ (1998) Effects of INS365,a P2Y2 receptor agonist, on components of the mucociliary clearance System. Pediatr Pulmonol Suppl 17:281

    Google Scholar 

  14. Everard ML, Devadason SG, Sunderland VB, Le Souef PN (1995) An alternative aerosol delivery System for amiloride. Thorax 50:517–519

    PubMed  CAS  Google Scholar 

  15. Folkesson HG, Matthey MA, Frigeri A, Verkman AS (1996) Transepithelial water permeability in microperfused distal airways. Evidence for channel-mediated water transport. J Clin Invest 97:664–671

    PubMed  CAS  Google Scholar 

  16. Graham A, Hasani A, Alton EWFW, Martin GP, Marriott C, Hodson ME, Clarke SW, Geddes DM (1993) No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 6:1243–1248

    PubMed  CAS  Google Scholar 

  17. Grygorczyk R, Hanrahan JW (1997) CFTR-independent ATP release from epithelial cells triggered by mechanical Stimuli. Am J Physiol 272: C1058–C1066

    PubMed  CAS  Google Scholar 

  18. Hofmann T, Böhmer O, Hüls G, Terbrack HG, Bittner P, Klingmüller V, Heerd E, Lindemann H (1997). Conventional and modified nasal potential difference measurement in cystic fibrosis. Am J Respir Crit Care Med 155:1908–1913

    PubMed  CAS  Google Scholar 

  19. Hofmann T, Senier I, Bittner P, Hüls G, Schwandt HJ, Lindemann H (1997) Aerosolized amiloride: Dose-effect on nasal bioelectric properties, pharmacokinetics and effect on Sputum expectoration in patients with cystic fibrosis. J Aerosol Med 10:147–158

    PubMed  CAS  Google Scholar 

  20. Hofmann T, Stutts J M, Ziersch A, Rückes C, Weber WM, Knowles MR, Lindemann H, Boucher RC (1998) Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am J Resp Crit Care Med 157:1844–1849

    PubMed  CAS  Google Scholar 

  21. Hull J, Skinner W, Robertson C, Phelan P (1998) Elemental content of airway surface liquid from infants with cystic fibrosis. Am J Respir Crit Care Med 157:10–14

    PubMed  CAS  Google Scholar 

  22. Jiang C, Finkbeiner WE, Widdicombe JH, Mc Cray PB, Jr, Miller SS (1993) Altered fluid transport across airway epithelium in cystic fibrosis. Science 262 (5132):424–427

    PubMed  CAS  Google Scholar 

  23. Knauf H, Reuter K, Mutschier E (1985) Limitation on the use of amiloride in early renal failure. Eur J Clin Pharmacol 28:61–66

    PubMed  CAS  Google Scholar 

  24. Krahl A, Geidel C, Alter H, Hofmann T, Bittner-Dersch P, Hüls G, Pabst J, Lindemann H (1998) Effective amiloride administration to CF-patients by powder inhalation. Pediatr Pulmonol Suppl 17:280 (abstract)

    Google Scholar 

  25. Knowles M, Carson JL, Collier, AM, Gatzy JT, Boucher, RC (1981) Measurement of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 124:484–490

    PubMed  CAS  Google Scholar 

  26. Knowles M, Gatzy J, Boucher R (1981) Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 305:1489–1495

    PubMed  CAS  Google Scholar 

  27. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher RC (1990) A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 322:1189–1194

    PubMed  CAS  Google Scholar 

  28. Knowles MR, Clarke LL, Boucher RC (1991) Activation of extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 325:533–538

    PubMed  CAS  Google Scholar 

  29. Knowles MR, Robinson JM, Wood RE, Pue CA, Mentz WM, Wager GC, Gatzy JT, Boucher RC (1997) Ion composition of airway surface liquid of patients with cystic fibrosis as compared to normal and disease-control subjects. J Clin Invest 100:2588–2595

    PubMed  CAS  Google Scholar 

  30. Köhler D, App, E, Schmitz-Schumann M, Würtemberger G, Matthys H (1986) Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibrosis. Eur J Respir Dis 69:319–326

    Google Scholar 

  31. Lansley AB, Sanderson MJ, Dirksen ER (1992) Control of the beat cycle of respiratory tract cilia by Ca2+ and cAMP. Am J Physiol 263: L232–L242

    PubMed  CAS  Google Scholar 

  32. Lethem MI, Dowell ML, Van Scott M, Yankaskas JR, Egan T, Boucher RC, Davis CW (1993) Nucleotide regulation of goblet cells in human airway epithelial explants: normal exocytosis in cystic fibrosis. Am J Respir Cell Mol Biol 9:315–322

    PubMed  CAS  Google Scholar 

  33. Lindemann H, Becker T, Bittner P, Boldt A, Hofmann T, Schwandt HJ (1990) Sekretelimination bei CF-Patienten unter Amiloridinhalation. Pneumologie 44:1148–50

    PubMed  CAS  Google Scholar 

  34. Lindemann H (1996) Amiloridinhalation. Pneumologie 50:841–844

    PubMed  Google Scholar 

  35. Mason SJ, Paradiso AM, Boucher RC (1991) Regulation of transepithelial ion transport and intracellular calcium by extracellular adenosine triphosphate in human normal and cystic fibrosis airway epithelium. Br J Pharmacol 103:1649–1656

    PubMed  CAS  Google Scholar 

  36. Mochizuki H, Shimizu T, Shigeta M, Tokuyama K, Morikawa A, Kuroume T (1994) Effect of inhaled amiloride on water-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 150:555–557

    PubMed  CAS  Google Scholar 

  37. Oh YS, Benos DJ (1992) Amiloride-sensitive sodium Channels. In: Cragoe EJ Jr, Kleyman T, Simchowitz L (eds) Amiloride and its analogs unique cation transport inhibitors, vol 4. VCH, New York, pp 41–56

    Google Scholar 

  38. Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC, Knowles MR (1996) Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate amiloride in normal human adults. Am J Respir Crit Care Med 154:217–223

    PubMed  CAS  Google Scholar 

  39. Pettis RJ, Knowles MR, Olivier KN, Hickey AJ (1996) Ionic interaction of amiloride and uridine 5′-triphosphate (UTP) in nebulizer Solutions. Am Assoc Pharmaceut Scientist Meeting

    Google Scholar 

  40. Pons G, Marchand MC, d’Athis P, Sauvage E, Foucard C, Chaumet-Riffaud P, Sautejeau A, Navarro J, Lenoir G and the Amiloride-AFLM collaborative study group (2000) French multicentre randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol 30:25–31

    PubMed  CAS  Google Scholar 

  41. Quinton PM (1994) Viscosity versus composition in airway pathology (editorial). Am J Respir Crit Care Med 149:6–7

    PubMed  CAS  Google Scholar 

  42. Regnis JA, Lazarowski ER, Foy CE, Boucher RC, Knowles MR (1996) Uridine 5′-triphosphate metabolism by human nasal epithelial cells, whole blood and plasma in vitro. Am J Respir Crit Care Med 153: (Suppl 4,2) A779 (abstract)

    Google Scholar 

  43. Robinson M, Regnis JA, Donnelly PM, Donnelly J Torzillo P, Beye PTP (1996) Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 153:1503–1509

    PubMed  CAS  Google Scholar 

  44. Smith JJ, Travis SM, Greenberg EP, Welsh MJ (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229–236; Erratum. Cell 87:355

    Google Scholar 

  45. Spahn H, Reuter K, Mutschier E, Gerok W, Knauf H. (1987) Pharmaco-kinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 33:493–498

    PubMed  CAS  Google Scholar 

  46. Stutts MJ, Milgram SL, Knowles MR, Boucher RC (1998) Molecular link of CFTR to other ion transport processes. Pediatr Pulmonol Suppl 17:121

    Google Scholar 

  47. Tomkiewicz RP, App EM, Zayas JG, Ramirez O, Church N, Boucher RC, Knowles MR, King M (1993) Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of Sputum. Am Rev Respir Dis 148:1002–1007

    PubMed  CAS  Google Scholar 

  48. Visca A, Bignamini E (1996) Concentration of inhaled amiloride in cystic fibrosis. Lancet 347:1126

    Google Scholar 

  49. Willumsen NJ, Davis CW, Boucher RC (1989) Intracellular Cl- activity and cellular Cl- pathways in cultured human airway epithelium. Am J Physiol 256 (5/1):C1033–C1044

    PubMed  CAS  Google Scholar 

  50. Ziersch A, Hofmann T, Geidel C, Krahl A, Senier I, Bittner-Dersch P, Hüls G, Lindemann H (1997) Ionentransportstörung bei CF: Additiver Effekt von Amilorid und hypertoner Kochsalzlösung. Monatsschr Kinderheilkd 145:314

    Google Scholar 

Liteatur zu 7.3.7

  1. Birrer P, McElvaney NG, Rüdeberg A, Wirz Sommer C, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150: 207–213

    PubMed  CAS  Google Scholar 

  2. Birrer P (1995) Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strate-gies. Respiration 62 (Suppl l):25–28

    PubMed  Google Scholar 

  3. McElvaney NG, Hubbard RG, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG (1991) Aerosol al-antitrypsin treatment for cystic fibrosis. Lancet 337:392–394

    PubMed  CAS  Google Scholar 

  4. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG (1992) Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 90: 1296–1301

    PubMed  CAS  Google Scholar 

  5. Schuster A, Hansen G, Zubrod-Eichert C, Wahn V (1996) Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic fibrosis Sputum: inhibition of neutrophil elastase activity and of sputum-induced secretion from porcine tracheal submucosal glands. Pediatr Res 40:732–737

    PubMed  CAS  Google Scholar 

  6. Tomee JFC, Koeter GH, Hiemstra PS, Kauffman HF (1998) Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic Option. Thorax 53:114–116

    PubMed  CAS  Google Scholar 

  7. Travis J, Fritz H (1991) Potential problems in designing elastase inhibitors for therapy. Am Rev Respir Dis 143:1412–1415

    PubMed  CAS  Google Scholar 

  8. Vogelmeier C, Gillissen A, Buhl R (1996) Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Chest 110:261S–266S

    PubMed  CAS  Google Scholar 

Liteatur zu 7.3.8

  1. App EM, Kieselmann R, Lindemann H (1998) Effects of Oszillation on the rheology of Sputum during inhalation with Solvet IL 22. European CF Conference, Berlin, 13. –19.6.98, Proceedings Book of Abstracts WP1–9

    Google Scholar 

  2. App EM, Kieselmann R, Reinhardt D, Lindemann H, Dasgupta B, King M, Brand P (1998) Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy — Flutter versus Autogenic Drainage. Chest 114:171–177

    PubMed  CAS  Google Scholar 

  3. App EM, Wunderlich MO, Lohse P, King M, Matthys H (1999) Oszillierende Physiotherapie bei Bronchialerkrankungen — Theologischer und antientzündlicher Effekt. Pneumologie 53:348–359

    PubMed  CAS  Google Scholar 

  4. Berger D (1979) Zur Effektivität des pursed-lips breathing. Atemw Lungenkrkh 5:12–15

    Google Scholar 

  5. Cegla UH, Bautz M, Frode G, Werner T (1997) Physiotherapie bei Patienten mit COAD und tracheobronchialer Instabilität — Vergleich zweier oszillierender PEP-Systeme (RC-Cornet, VPR1 Desitin). Pneumologie 51:129–136

    PubMed  CAS  Google Scholar 

  6. Chevaillier J, Franckx H, Kraemer R (1987) Autogene Drainage — physiotherapeutisches Prinzip und Wirkungsweise. Prax Klin Pneumol 41:573–575

    Google Scholar 

  7. Criée CP, Laier-Groeneveld (1995) Die Atempumpe — Atemmuskulatur und intermittierende Selbstbeatmung. Thieme, Stuttgart New York

    Google Scholar 

  8. Dab I, Alexander F (1979) The mechanism of autogenic drainage studied with flow volume curves. Monogr Paediatr 10:50–53

    PubMed  CAS  Google Scholar 

  9. Dautzenroth A, Spindel G (1998) Passive Techniken. In: Mukoviszidose e.V. (Hrsg) Physiotherapie bei Mukoviszidose, 3. Aufl. Mukoviszidose Service GmbH, Bonn, S 22–51

    Google Scholar 

  10. Ehrenberg H (1998) Der Einsatz der dosierten und langen Lippenbremse bei Mukoviszidose. In: Mukoviszidose e.V. (Hrsg) Physiotherapie bei Mukoviszidose, 3. Aufl. Mukoviszidose Service GmbH, Bonn, S 95

    Google Scholar 

  11. Falk M, Kelstrup M, Andersen JB, Kinoshita T, Falk P, Stovring I, Gothgen I (1984) Improving the ketchup bottle method with positive expiratory pressure, pep. A control-led study in patients with cystic fibrosis. Eur J Respir Dis 65:57-66

    Google Scholar 

  12. Gruber W, Leister E, Linse P (1998) Körperliche Aktivität und Sport in der Behandlung von Patienten mit Mukoviszidose. In: Mukoviszidose e.V. (Hrsg) Physiotherapie bei Mukoviszidose, 3. Aufl. Mukoviszidose Service GmbH, Bonn, S 117–121

    Google Scholar 

  13. Heeckt D (1998) Die PEP-Atmung. In: Mukoviszidose e. V. (Hrsg) Physiotherapie bei Mukoviszidose, 3. Aufl. Mukoviszidose Service GmbH, Bonn, S 86–90

    Google Scholar 

  14. Hüls G, Boldt A, Lindemann H (1988) Effektivitätsvergleich zwischen dosierter und leicht forcierter PEP-Maskenatmung (erste Ergebnisse). In: Lindemann H (Hrsg) Fortschritte in Diagnostik und Therapie der Mukoviszidose. Borek, Braunschweig, S 57–61

    Google Scholar 

  15. Kieselmann R (1998) Modifizierte Autogene Drainage. In: Mukoviszidose e.V. (Hrsg)  Physiotherapie bei Mukoviszidose, 3. Aufl. Mukoviszidose Service GmbH, Bonn, S 78–85

    Google Scholar 

  16. Kieselmann R, App EM, Lindemann H (1998) Physiotherapy under influence of oszillation with different frequencies. 22. European CF Conference, Berlin, 13.–19.6.98, Proceedings WP1–10 (Abstract)

    Google Scholar 

  17. Köhler D, Fischer W (1988) Was ist gesichert in der Inhalationstherapie? Arcis

    Google Scholar 

  18. Lindemann H (1992) Zum Stellenwert der Physiotherapie mit dem VRP 1-Desitin („Flutter“). Pneumologie 46:626–630

    PubMed  CAS  Google Scholar 

  19. Lindemann H, Boldt A, Kieselmann R (1990) Autogenic drainage: Effkacy of a simplified method. Acta Univ Carol Med 36:210–212

    CAS  Google Scholar 

  20. Lindemann H, Leupold W, Niggemann B (1997) Lungenfunktionsdiagnostik bei Kindern. Kohlhammer, Stuttgart Köln

    Google Scholar 

  21. Mallol J, Rattray S, Walker G, Cook D, Robertson CF (1996) Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 21:276–281

    PubMed  CAS  Google Scholar 

  22. Mukoviszidose e.V., Arbeitskreis Physiotherapie (1998) Physiotherapie bei Mukoviszidose, 3. Aufl. Mukoviszidose Service GmbH, Bonn

    Google Scholar 

  23. Schlemper B, Bittner P, Lindemann H (1986) Combination of PEP-mask-breathing with conventional inhalation in patients with cystic fibrosis. Eur Soc Respir Cardiovasc Physiotherapy, Stresa, 16. –18.10.86

    Google Scholar 

  24. Schumacher H (1998) Das Trampolin als Therapiegerät. . In:Mukoviszidose e.V. (Hrsg)  Physiotherapie bei Mukoviszidose, 3. Aufl. Mukoviszidose Service GmbH, Bonn, S 111–112

    Google Scholar 

  25. Siemon G (1985) Physikalische Atemtherapie bei obstruktiven Atemwegserkrankungen. In: Ferlinz R, Lichterfeld A, Steppling (Hrsg) Stufentherapie der Atemwegsobstruktion. Thieme, Stuttgart New York

    Google Scholar 

  26. Siemon G (1994) Inhalt und Erfolge [der physikalischen Therapie]. In: Petro W (Hrsg) Pneumologische Prävention und Rehabilitation. Springer, Berlin Heidelberg New York Tokio, S 387–395

    Google Scholar 

  27. Sommerwerck D (1981) Atemtherapie und Rechtsherzinsuffizienz. Kongreßbericht Wiss Tagg Norddeutsche Ges Lungen- und Bronchialheilkunde 17:107–113

    Google Scholar 

  28. Tammeling GJ, Quanier PH (1980) Physiologie der Atmung. Thomae, Thomae

    Google Scholar 

  29. Voshaar T, Köhler D (1996) Effects of physiotherapy with the VRP1 Desitin and huffing on lung function and bronchial clearance. Stud Pneumol Phtiseo 56:147–152

    Google Scholar 

  30. Weibel E (1963) Morphometry of the human lung. Springer, Heidelberg

    Google Scholar 

  31. Weise S (1992) Techniken der Sekretelimination bei Frühgeborenen, Säuglingen und Kindern in der frühen postoperativen Phase. Krankengymnastik 44:967–979

    Google Scholar 

  32. Zach M, Oberwaldner B (1988) Forcierte Exspiration gegen einen externen Widerstand; eine neue Methode der PEP-Masken-Physiotherapie bei CF. In: Schumacher H (Hrsg) Siebte Ambulanzärztetagung. Gödecke AG, Berlin Freiburg

    Google Scholar 

Liteatur zu 7.3.9

  1. Andréasson B, Jonson B, Kornfält R, Nordmark E, Sandström S (1987) Long-term effects of physical exercise on working capacity and pulmonary function in cystic fibrosis. Acta Paediatr Scand 76:70–75

    PubMed  Google Scholar 

  2. Bar-Or O, Blimkie CJ, Hay JD, Macdougall JD, Ward DS, Wilson WM (1992) Voluntary dehydration and heat intolerance in cystic fibrosis. Lancet 339:696–699

    PubMed  CAS  Google Scholar 

  3. Benson LN, Newth CJ, Desouza M, Lobraico R, Kartodihardjo W, Corkey C, Gilday D, Olley PM (1984) Radionuclide assessment of right and left ventricular function during bicycle exercise in young patients with cystic fibrosis. Am Rev Respir Dis 130:987–992

    PubMed  CAS  Google Scholar 

  4. Boas SR (1997) Exercise recommendations for individuals with cystic fibrosis. Sports Med 24:17–37

    PubMed  CAS  Google Scholar 

  5. Boas SR, Joswiak ML, Nixon APA, Fulton JA, Orenstien DM (1996) Factors limiting anaerobic Performance in adolescent males with cystic fibrosis. Med Sei Sports Exerc 28 (3): 291–298

    CAS  Google Scholar 

  6. Cadarette BS, Sawka MN, Toner MM, Pandolf KB (1984) Ärobic fitness and the hypohydration response to exercise-heat stress. Aviat Space Environ Med 55:507–512

    PubMed  CAS  Google Scholar 

  7. Campbell M, Emanuel R (1967) Six cases of congenital complete heart block followed for 34–40 years. Br Heart J 29:577–587

    PubMed  CAS  Google Scholar 

  8. Campbell RD, McKelvie RS, Heigenhauser GJF, Jones NL (1989) Estimation of cardiac Output by CO2 rebreathing during incremental exercise in patients with coronary artery disease. Am J Noninvas Cardiol 3:147–153

    Google Scholar 

  9. Cerny FJ, Cropp GJA, Bye MR (1984) Hospital therapy improves exercise tolerance and lung function in cystic fibrosis. AJDC 138:261–265

    PubMed  CAS  Google Scholar 

  10. Chipps BE, Alderson PO, Roland JMA, Yang AV, Martinez CR, Rosenstein BJ (1979) Non-invasive evaluation of ventricular function in cystic fibrosis. J Pediatr 95:379–384

    PubMed  CAS  Google Scholar 

  11. Coates AL, Boyce P, Muller D, Mearns M, Godfrey S (1980) The role of nutritional Status, airway obstruction, hypoxia, and abnormalities in serum lipid composition in limiting exercise tolerance in children with cystic fibrosis. Acta Paediatr Scand 69:353–358

    PubMed  CAS  Google Scholar 

  12. Cropp GJA, Pullano TP, Cerny FJ, Nathanson IT (1982) Exercise tolerance and cardiorespiratory adjustments at peak work capacity in cystic fibrosis. Am Rev Respir Dis 126:211–216

    PubMed  CAS  Google Scholar 

  13. de Jong W, Grevink RG, Roorda RJ, Kaptein AA, van der Schans CP (1994) Effect of a home exercise training program in patients with cystic fibrosis. Chest 105:463–468

    PubMed  Google Scholar 

  14. de Meer K, Jeneson JA, Gulmans VA, van der Laag J, Berger R (1995) Efficiency of oxidative work Performance of skeletal muscle in patients with cystic fibrosis. Thorax 50: 980–983

    PubMed  Google Scholar 

  15. Godfrey S, Mearns M (1971) Pulmonary function and responses to exercise in cystic fibrosis. Arch Dis Child 46: 144–151

    PubMed  CAS  Google Scholar 

  16. Gulmans VA, van Veldhoven NH, de Meer K, Helders PJ (1996) The six-minute Walking test in children with cystic fibrosis. Pediatr Pulmonol 22:85–89

    PubMed  CAS  Google Scholar 

  17. Hanning RM, Blimkie CJR, Bar-Or O, Lands LC, Moss LA, Wilson WM (1993) Relationships among nutritional Status and skeletal and respiratory muscle function in cystic fibrosis: does early dietary supplementation make a difference? Am J Clin Nutr 57:580–587

    PubMed  CAS  Google Scholar 

  18. Heijerman HGM, Bakker W, Sterk PJ, Dijkman JH (1992) Long-term effects of exercise training and hyperalimentation in adult cystic fibrosis patients with severe pulmonary dysfunction. Int J Rehab Research 15:252–257

    CAS  Google Scholar 

  19. Henke KG, Orenstein DM (1984) Oxygen Saturation during exercise in cystic fibrosis. Am Rev Respir Dis 129:708–711

    PubMed  CAS  Google Scholar 

  20. Holzer FJ, Olinsky A, Phelan PD (1981) Variability of airways hyperreactivity and allergy in cystic fibrosis. Arch Dis Child 56:455–459

    PubMed  CAS  Google Scholar 

  21. Keens TG, Krastins IR, Wannamaker EM, Levison H, Crozier ON, Bryan C (1977) Ventilatory muscle endurance training in normal subjects and patients with cystic fibrosis. Am Rev Respir Dis 116:853–860

    PubMed  CAS  Google Scholar 

  22. Kriemler S, Wilk B, Schurer W, Wilson WM, Bar-Or O (1999) Preventing dehydration in children with cystic fibrosis who exercise in the heat. Med Science Sports Exerc 31:774–779

    CAS  Google Scholar 

  23. Levison H, Cherniack RM (1968) Ventilatory cost of exercise in chronic obstructive pulmonary disease. J Appl Physiol 25:21–27

    PubMed  CAS  Google Scholar 

  24. Moorcroft AJ, Dodd ME, Webb AK (1998) Exercise limitations and training for patients with cystic fibrosis. Disability Rehab 20:247–253

    CAS  Google Scholar 

  25. Nixon PA, Orenstein DM, Curtis SE, Ross EA (1990) Oxygen supplementation during exercise in cystic fibrosis. Am Rev Respir Dis 142:807–811

    PubMed  CAS  Google Scholar 

  26. Nixon PA, Orenstein DM, Kelsey Sf, Doershuk CF (1992) The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 327:1785–1788

    PubMed  CAS  Google Scholar 

  27. Oades PJ, Buchdahl RM, Bush A (1994) Prediction of hypxaemia at high altitude in children with cystic fibrosis. Br Med J 308:15–18

    CAS  Google Scholar 

  28. Orenstein DM (1981) Exercise in the heat in cystic fibrosis patients. Med Sei Sports Exerc 13:91(Abstract)

    Google Scholar 

  29. Orenstein DM, Eigen H, Brooks J, Greene H, Redding G, Waring W (1995) Cystic fibrosis and exercise: A beginner’s guid. (unpublished)

    Google Scholar 

  30. Orenstein DM, Franklin BA, Doershuk CF, Hellerstein HK, Germann KJ, Horowitz JG, Stern RC (1981) Exercise conditioning and cardiopulmonary fitness in cystic fibrosis. The effects of a three-month supervised running program. Chest 80:392–398

    PubMed  CAS  Google Scholar 

  31. Orenstein DM, Nixon PA, Ross EA, Kaplan RM (1989) The quality of well-being in cystic fibrosis. Chest 95:344–347

    PubMed  CAS  Google Scholar 

  32. Price JF, Weller PH, Harper SA, Metthew DJ (1979) Response to bronchial provocation and exercise in children with cystic fibrosis. Clin Allergy 9:563–570

    PubMed  CAS  Google Scholar 

  33. Silverman M, Hobbs FD, Gordon IR (1978) Cystic fibrosis, atopy and airways lability. Arch Dis Child 53:873–878

    PubMed  CAS  Google Scholar 

  34. Strauss GD, Osher A, Wang C-I, Goodrich E, Gold F, Colman W, Stabile M, Dobrenchuck A, Keens TG (1987) Variable weight training in cystic fibrosis. Chest 92:273–276

    PubMed  CAS  Google Scholar 

  35. Webb AK, Dodd ME, Moorcroft J (1995) Exercise in cystic fibrosis. J R Soc Med 88 (Suppl): 30–36

    PubMed  Google Scholar 

Liteatur zu 7.3.10

  1. Adlard P, Bryett K (1987) Influenza immunization in children with cystic fibrosis. J Intern Med Res 15:344–351

    CAS  Google Scholar 

  2. Ferson M, Morton J, Robertson P (1991) Impact of influenza on morbidity in children with cystic fibrosis. J Paediatr Child Health 27:308–311

    PubMed  CAS  Google Scholar 

  3. Gross P, Denning C, Gaerlan P, Bonelli J, Bernius M, Dran S, Monk G, Vassallo M, Quinnan G, Levandowski R, Cataruozolo P, Wallenstein S (1996) Annual influenza vaccination: immune response in patients over 10 years. Vaccine 14: 1280–1284

    PubMed  CAS  Google Scholar 

  4. Huber E, Rannon L, Galffy G (1976) Langzeitstudie nach Masernimpfung. Pädiatr Pädol 11:72–76

    PubMed  CAS  Google Scholar 

  5. MacDonald P, Morris R, Beaudry P (1987) Varicella in children with cystic fibrosis. Pediatr Infect Dis J 6:414–416

    PubMed  CAS  Google Scholar 

  6. Ong E, Bilton D, Abbott J, Webb A, McCartney R, Caul E (1991a) Influenza vaccination in adults with cystic fibrosis. Br Med J 303:557–557

    Google Scholar 

  7. Ong E, Mulvenna P, Webb K (1991b) Varicella-zoster infection in adults with cystic fibrosis: role of acyclovir. Scand J Infect Dis 23:283–285

    Google Scholar 

  8. Piedra P, Grace S, Jewell A, Spinell S, Hogerman D, Malinoski F, Hiatt P (1998) Sequential annual administration of purified fusion protein Vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 17:217–224

    PubMed  CAS  Google Scholar 

  9. Piedra P, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman D, Malinoski F, Hiatt P (1996) Purified fusion protein Vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 15:23–31

    PubMed  CAS  Google Scholar 

  10. Pribble C, Black P, Bosso J, Turner R (1990) Clinical manifestations of exacerbations of cystic fibrosis associated with non-bacterial infections. J Pediatr 117:200–204

    PubMed  CAS  Google Scholar 

  11. Stiko C. (2000) Mitteilung der Ständigen Impfkommission am Robert-Koch-Institut. Epidemiol Bull 9–20

    Google Scholar 

Liteatur zu 7.4.1

  1. Bingle L, Tetley TD (1996) Secretory leukoproteinase inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. Thorax 51:1273–1274

    PubMed  CAS  Google Scholar 

  2. Friedman PJ, Harwood IR, Ellenbogen PH (1981) Pulmonary cystic fibrosis in the adult: Early and late radiologic findings with pathologic correlation. Am J Radiol 136: 1131–1144

    CAS  Google Scholar 

  3. Kramer MR, Jakobson DJ, Springer C, Donchin Y (1995) The safety of air transport of patients with advanced lung disease. Experience with 21 patients requiring lung transplantation or pulmonary thromboendarterectomy. Chest 108:1292–1296

    PubMed  CAS  Google Scholar 

  4. Stern RC (1993) Pulmonary complications. In: Davis PB (ed) Cystic fibrosis. Lung biology in health and disease. Marcel Dekker, New York, S 352–353

    Google Scholar 

Liteatur zu 7.4.2

  1. Battistini A, Grzincich GL, Grandi F, Ferrara D, Carchesio I, Pistocchi S (1983) Aerosol administration in antibiotic therapy of cystic fibrosis. Pediatr Med Chir 5:161–169

    PubMed  CAS  Google Scholar 

  2. di Sant’Agnese PA (1953) Bronchial obstruction with lobar atelectasis and emphysema in cystic fibrosis of the pancreas. Pediatrics 12:178–190

    Google Scholar 

  3. Friedman PJ, Harwood IR, Ellenbogen PH (1981) Pulmonary cystic fibrosis in the adult: Early and late radiologic findings with pathologic correlation. Am J Radiol 136:1131–1144

    CAS  Google Scholar 

  4. Grum CM, Lynch JP (1992) Chest radiographic findings in cystic fibrosis. Semin Respir Infect 7:193–209

    PubMed  CAS  Google Scholar 

  5. Nussbaum E (1985) Pediatric flexible bronchoscopy and its application in infantile atelectasis. Clin Pediatr (Phila) 24:379–382

    CAS  Google Scholar 

  6. Shah PL, Scott SF, Hodson ME (1994) Lobar atelectasis in cystic fibrosis and treatment with recombinant human DNase I. Respir Med 88:313–315

    PubMed  CAS  Google Scholar 

  7. Stern RC, Boat TF, Orenstein DM, Wood R, Matthews LW, Doershuk CF (1978) Treatment and prognosis of lobar and segmental atelectasis in cystic fibrosis. Am Rev Respir Dis 118:821–826

    PubMed  CAS  Google Scholar 

  8. Stern RC (1993) Pulmonary complications. In: Davis PB (ed) Cystic fibrosis. Lung biology in health and disease. Marcel Dekker, New York, pp 352–353

    Google Scholar 

  9. Taccone A, Romano L, Marzoli A, Girosi D, Dell’PAcqua A, Romano C (1992) High-resolution computed tomography in cystic fibrosis. Eur J Radiol 15:125–129

    PubMed  CAS  Google Scholar 

Liteatur zu 7.4.3

  1. Aebersold A, Schaad UB (1991) Pneumothorax in cystic fibrosis. Schweiz Med Wochenschr 121:174–181

    PubMed  CAS  Google Scholar 

  2. Huang NN, Schidlow DV, Szatrowski TH, Palmer J, Laraya-Cuasay LR, Yeung W, Hardy K, Quitrell L, Fiel S (1987) Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. Am J Med 82:871–879

    PubMed  CAS  Google Scholar 

  3. Mc Laughlin FJ, Matthews WJ, Strieder DJ, Khaw KT, Schuster S, Shwachman H (1982) Pneumothorax in cystic fibrosis: Management and outcome. J Pediatr 100:863–869

    CAS  Google Scholar 

  4. Noppen M, Dhandt E, Mahler T, Malfroot A, Dab I, Vincken W (1994) Successful management of recurrent pneumothorax in cystic fibrosis by localized apical thoracoscopic talc poudrage. Chest 106:262–264

    PubMed  CAS  Google Scholar 

  5. Penketh ARL, Wise A, Mearns MB, Hodson ME, Batten JC (1987) Cystic fibrosis in adolescent and adults. Thorax 42:526–532

    PubMed  CAS  Google Scholar 

  6. Spector ML, Stern RC (1989) Pneumothorax in cystic fibrosis: A 26-year experience. Ann Thorac Surg 47:204–207

    PubMed  CAS  Google Scholar 

  7. Schidlow D, Taussig LM, Knowles MR (1993) Cystic fibrosis foundation consensus Conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 15:187–198

    PubMed  CAS  Google Scholar 

Liteatur zu 7.4.4

  1. Cipolli M, Perini S, Valletta EA, Mastella G (1995) Bronchial artery embolization in the management of hemoptysis in cystic fibrosis. Pediatr Pulmonol 19:344–347

    PubMed  CAS  Google Scholar 

  2. Fabian MC, Smitheringale A (1996) Hemoptysis in children: the hospital for sick children experience. J Otolaryngol 25:44–45

    PubMed  CAS  Google Scholar 

  3. Schidlow D, Taussig LM, Knowles MR (1993) Cystic fibrosis foundation consensus Conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 15:187–198

    PubMed  CAS  Google Scholar 

  4. Stern RC (1993) Pulmonary complications. In: Davis PB (ed) Cystic fibrosis. Lung biology in health and disease. Marcel Dekker, New York, pp 352–353

    Google Scholar 

  5. Reinhardt D, Schneider K (1996) Schwere Hämoptoe bei Mukoviscidose. Monatsschr Kinderheilkd 144:555–556

    Google Scholar 

Liteatur zu 7.4.5

  1. Aron Y, Polla BS, Bienvenue T, Dall’ava J, Dusser G, Hubert D (1999) HLA-class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype. Am J Respir Crit Care Med 159:1464–1468

    PubMed  CAS  Google Scholar 

  2. Becker JW, Burke W, McDonald G (1996) Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 109:1536–1540

    PubMed  CAS  Google Scholar 

  3. Burnie JP (1995) Allergie and invasive aspergillosis. J R Soc Med 88(Suppl25):41–45

    PubMed  Google Scholar 

  4. Crameri R (1998) Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications. Int Arch Allergy Immunol 115:99–114

    PubMed  CAS  Google Scholar 

  5. Crameri R, Blaser K (1996) Cloning Aspergillus fumigatus allergens by the the pJuFo filamentous phage display System. Int Arch Allergy Immunol 110:41–45

    PubMed  CAS  Google Scholar 

  6. Feanny S, Forsyth S, Corey M, Levison H, Zimmermann B (1988) Allergie bronchopulmonary aspergillosis in cystic fibrosis: a secretory immune response to a colonizing organism. Ann Allergy 60:64–8

    PubMed  CAS  Google Scholar 

  7. Greally P, Cook AJ, Sampson AP, Coleman R, Chambers S, Piper PJ, Price JF (1994) Atopic children with cystic fibrosis have increased urinary leukotriene E4 concentrations and more severe pulmonary disease. J Allergy Clin Immunol 93:100–7

    PubMed  CAS  Google Scholar 

  8. Greenberger PA (1988). Allergie bronchopulmonary aspergillosis and fungoses. Clin Chest Med 9:599–608

    PubMed  CAS  Google Scholar 

  9. Hemmann St, Nikolaizik WH, Schöni MH, Blaser K, Crameri R (1998) Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or aspergillus allergy. Eur J Immunol 28:1155–1160

    Google Scholar 

  10. Hinson KFW, Moon AJ, Plummer NS (1952) Bronchopulmonary aspergillosis. Thorax 7:317–333

    PubMed  CAS  Google Scholar 

  11. Jennings TS, Hardin TC (1993) Treatment of aspergillosis with itraconazole. Ann Pharmacother 27:1206–1211

    PubMed  CAS  Google Scholar 

  12. Kauffmann HF, van der Heide S, Beaumont F, de Monchy JGR, de Vries K (1984) The allergenic and antigenic properties of spore extracts of Aspergillus fumigatus: a comparative study of spore extracts with mycelium and culture ltrate extracts. J Allergy Clin Immunol 73:567–573

    Google Scholar 

  13. Kauffman HF, van der Heide S, van der Laan S, Hovenga H, Beaumont F, de Vries K (1985) Standardisation of allergenic extracts of Aspergillus fumigatus. Liberation of IgE-binding component during cultivation. Int Arch Allergy Immunol 76:168–173

    CAS  Google Scholar 

  14. Kauffman HF, de Vries K (1980) Antibodies against Aspergillus fumigatus. I. Standardisation of the antigenic composition. Int Arch Allergy Immunol 62:252–264

    CAS  Google Scholar 

  15. Laufer P, Fink JN, Bruns WT, Unger GF, Kalbfleisch JH, Greenberger PA, Patterson P (1984) Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol 73:44–48

    PubMed  CAS  Google Scholar 

  16. Leon EE, Craig TJ (1999) Antifungals in the treatment of allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 82:511–517

    PubMed  CAS  Google Scholar 

  17. Longbottom JL, Austwick PKC (1986) Antigens and allergens of Aspergillus fumigatus. I. Characterisation by quantitative immunoelectrophoretic techniques. J Allergy Clin Immunol 78:9–17

    PubMed  CAS  Google Scholar 

  18. Mearns M, Young W, Batten J (1965) Transient pulmonary infiltration in Cystic Fibrosis due to allergic aspergillosis. Thorax 20:385–92

    Google Scholar 

  19. Mannes GP, van der Heide S, van Aalderen WM (1993) Itraconazole and allergic bronchopulmonary aspergillosis in twin brothers with cystic fibrosis. Lancet 341:492

    PubMed  CAS  Google Scholar 

  20. Moser M, Crameri R, Menz G, Schneider T, Dudler T, Virchow C, Gmach M, Blaser K, Suter M (1992) Cloning and expression of recombinant Aspergillus fumigatus allergen I/a (rAsp f I/a) with IgE binding and type 1 skin test activity. J Immunol 49:454–460

    Google Scholar 

  21. Nelson LA, Callerame ML, Schwartz RH (1979) Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis 120:863–873

    PubMed  CAS  Google Scholar 

  22. Nikolaizik WH, Moser M, Crameri R, Little S, Warner JO, Blaser K, Schöni MH (1995) Identification of allergic bronchopulmonary aspergillosis in cystic fibrosis patients with recombinant aspergillus fumigatus I/a specific serology. Am J Respir Crit Care Med 152:634–639

    PubMed  CAS  Google Scholar 

  23. Nikolaizik WH, Brueton MJ, Warner JO (1991) Aspergillus allergy and allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Allergy Immunol 2:83–86

    Google Scholar 

  24. Patterson R, Greenberger PA, Radin RC, Roberts M (1982) Allergic bronchopulmonary aspergillosis: Staging as an aid to management. Ann Intern Med 96:286–292

    PubMed  CAS  Google Scholar 

  25. Sammuelson H, Karlsson-Borg A, Paulsen BS, Wold JK (1991) Purification of a 20 kD allergen from Aspergillus fumigatus. Allergen 46:115–24

    Google Scholar 

  26. Scheiner O (1992) Recombinant allergens: biological, immunological and practical aspects. Int Arch Allergy Immunol 98:93–96

    PubMed  CAS  Google Scholar 

  27. Silvermann M, Hobbs FD, Gordon IR, Carswell F (1978). Cystic fibrosis, atopy and airways lability. Arch Dis Child 53:873–877

    Google Scholar 

  28. Simmonds EJ, Littlewood JM, Evans EGV (1990) Cystic fibrosis and allergic bronchopulmonary aspergillosis. Arch Dis Child 65:507–511

    PubMed  CAS  Google Scholar 

  29. Skov M, Poulsen LK, Koch C (1999) Increased antigen-specific Th2 response in allergic bronchopulmonary aspergillosin patients with cystic fibrosis. Pediatr Pulmonol 27:74–79

    PubMed  CAS  Google Scholar 

  30. Warner JO, Taylor BW, NormanAP, Soothill JF (1976) Association of cystic fibrosis with allergy. Arch Dis Child 51:507–511

    PubMed  CAS  Google Scholar 

  31. Williams PB, Nolte H, Dolen WK, Koepke JW, Seiner JC (1992) The histamine content of allergen extracts. J Allergy Clin Immunol 89:738–745

    PubMed  CAS  Google Scholar 

Liteatur zu 7.4.6

  1. Bell SC, Eibron JS, Campbell IA, Shale DJ (1995) Candida albicans infection complicating percutaneous gastrostomy in cystic fibrosis. Br J Clin Pract 49:109–110

    PubMed  CAS  Google Scholar 

  2. Bhargava V, Tomashefski JF, Stern RC, Abramowski CR (1989) The pathology of fungal infection and colonization in patients with cystic fibrosis. Hum Pathol 20:977–986

    PubMed  CAS  Google Scholar 

  3. Bonacorsi SP, Munck A, Gerardin M, Doit C, Brahimi N, Navarro J, Bingen E (1996) In situ management and molecular analysis of candidaemia related to a totally implantable vascular access in a cystic fibrosis patient. J Infect 33:49–51

    PubMed  CAS  Google Scholar 

  4. Brown K, Rosenthal M, Bush A (1999) Fatal invasive aspergillosis in an adolescent with cystic fibrosis. Pediatr Pulmonol 27:130–133

    PubMed  CAS  Google Scholar 

  5. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL (1999) Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190–1196

    PubMed  CAS  Google Scholar 

  6. Chung Y, Kraut JR, Stone AM, Valaitis J (1994) Disseminated aspergillosis in a patient with cystic fibrosis and allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 17:131–134

    PubMed  CAS  Google Scholar 

  7. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, Sylvester R, Meis J, Boogaerts M, Selleslag D, Krcmery V, von Sinner W, MacDonald P, Doyen C, Vandercam B (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27:1406–1412

    PubMed  CAS  Google Scholar 

  8. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR (1994) Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 149:1601–1607

    PubMed  CAS  Google Scholar 

  9. Guidotti TL, Luetzeler J, di Sant’Agnese PA, Escaro DU (1982) Fatal disseminated aspergillosis in a previously well young adult with cystic fibrosis. Am J Med Sei 283:157–160

    CAS  Google Scholar 

  10. Kanj SS, Tapson V, Davis RD, Madden J, Browning I (1997) Infections in patients with cystic fibrosis following lung transplantation. Chest 112:924–930

    PubMed  CAS  Google Scholar 

  11. Kusenbach G, Skopnik H, Haase G, Friedrichs F, Dohmen H (1992) Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 151:344–346

    PubMed  CAS  Google Scholar 

  12. Maguire CP, Hayes JP, Hayes M, Masterson J, FitzGerald MX (1995) Three cases of pulmonary aspergilloma in adult patients with cystic fibrosis. Thorax 50:805–806

    PubMed  CAS  Google Scholar 

  13. Nunley DR, Ohori P, Grgurich WF, Iacono AT, Williams PA, Keenan RJ, Dauber JH (1998) Pulmonary aspergillosis in cystic fibrosis lung transplant reeipients. Chest 114X:1321–1329

    Google Scholar 

  14. Sammut PH, Howard ST, Linder J, Colombo JL (1993) Unusual form of endobronchial aspergillosis in a patient with cystic fibrosis. Pediatr Pulmonol 16:69–73

    PubMed  CAS  Google Scholar 

Liteatur zu 7.4.7

  1. Bowden DH, Fischer VW, Wyatt JP (1965) Cor pulmonale in cystic fibrosis. Am J Med 38:226–232

    PubMed  CAS  Google Scholar 

  2. British Medical Research Council Working Party (1981) Long-term domiciliary oxygen therapy in chronic hypoxaemic cor pulmonale complicating chronic bronchitis and emphysema. Lancet i:681–686

    Google Scholar 

  3. Brownlee JB, Beekman RH, Rosenthal A (1988) Acute hemodynamic effects of nifedipine with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res 24:186–190

    PubMed  CAS  Google Scholar 

  4. Burghuber OC, Salzer-Muhar U, Bergmann H, Götz M (1988) Right ventricular Performance and pulmonary haemodynamics in adolescent and adult patients with cystic fibrosis. Eur J Pediatr 148:187–192

    PubMed  CAS  Google Scholar 

  5. Burghuber OC, Salzer-Muhar U, Götz M (1988) Right ventricular contractility is preserved in patients with cystic fibrosis and pulmonary artery hypertension. Scand J Gastroenterol Suppl 143:93–98

    PubMed  CAS  Google Scholar 

  6. Burghuber OC, Hartter E, Weissei M, Wolosczuk W, Götz M (1991) Raised circulating plasma levels of atrial natriuretic peptide in adolescent and adult patients with cystic fibrosis and pulmonary artery hypertension. Lung 169: 291–300

    PubMed  CAS  Google Scholar 

  7. Canny GJ, de Souza ME, Gilday ML, Newth CJ (1984) Radionuclide assessment of cardiac Performance in cystic fibrosis. Reproducibility and effect of theophylline on cardiac function. Am Rev Respir Dis 130:822–826

    PubMed  CAS  Google Scholar 

  8. Caronia CG, Silver P, Nimkoff L, Gorvoy J, Quinn C, Sagy M (1998) Use of bilevel positive airway pressure (BIPAP) in end-stage patients with cystic fibrosis awaiting lung transplantation. Clin Pediatr 37:555–559

    CAS  Google Scholar 

  9. Davidson A, Bossuyt A, Dab I (1989) Acute effects of oxygen, nifedipine, and diltiazem in patients with cystic fibrosis and mild pulmonary hypertension. Pediatr Pulmonol 6:53–59

    PubMed  CAS  Google Scholar 

  10. Deschamps J-P, Didier F, Floquet J (1971) Mucoviscidose revelée et dominée par ses manifestations cardiaques. Arch Franç Péd 28:417–424

    CAS  Google Scholar 

  11. Eichler I, Burghuber OC, Götz M (1990) Acute effects on pulmonary haemodynamics of nifedipine in adult patients with cystic fibrosis. Eur J Clin Pharmacol 39:57–588

    Google Scholar 

  12. Fauroux B, Boule M, Lafaso F, Zerah F, Clement A, Harf A, Isabey D (1999) Chest physiotherapy in cystic fibrosis: improved tolerance with nasal pressure support Ventilation. Pediatricsl03: E32

    Google Scholar 

  13. Fraser KL, Tullis DE, Sasson Z, Hyland RH, Thornley KS, Hanly PJ (1999) Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 115:1321–1328

    PubMed  CAS  Google Scholar 

  14. GAP Conference Report (1980) Cor pulmonale, 4: iii-36. Cystic Fibrosis Foundation, Rockville, Maryland

    Google Scholar 

  15. Goldring RM, Fishman AP, Turino GM, Cohen HI, Denning CR, Andersen DH (1964) Pulmonary hypertension and cor pulmonale in cystic fibrosis of the pancreas 65:501–524

    Google Scholar 

  16. Götz MH, Burghuber OC, Salzer-Muhar U, Wolosczuk W, Weissei M, Hartter E (1989) Cor pulmonale in cystic fibrosis. J R Soc Med 82 (Suppl 16):26–31

    PubMed  Google Scholar 

  17. Granton JT, Kesten S (1998) The acute effects of nasal positive pressure Ventilation in patients with advanced cystic fibrosis. Chest 113:1013–1018

    PubMed  CAS  Google Scholar 

  18. Hill AT, Edenborough FP, Cayton RM, Stableforth DF (1998) Long-term nasal intermittent positive pressure Ventilation in patients with cystic fibrosis and hypercapnic respiratory failure (1991–1996). Respir Med 92:523–526

    PubMed  CAS  Google Scholar 

  19. Hume JR, Hart P, Levesque PC, Collier ML, Geary Y, Warth J, Chapman T, Horowitz B (1994) Molecular physiology of CFTR Cl’-channels in heart. Jpn J Physiol 44 (Suppl 2): S177–S182

    PubMed  CAS  Google Scholar 

  20. Johnson GL, Kanga JF, Moffett CB, Noonan JA (1991) Changes in left ventricular diastolic filling patterns by Doppler echocardiography in cystic fibrosis. Chest 99:646–650

    PubMed  CAS  Google Scholar 

  21. Kovesi TA, Lehotay Dc, Levison H (1994) Plasma carnitine levels in cystic fibrosis. J Pediatr Gastroenterol Nutr 19:421–424

    PubMed  CAS  Google Scholar 

  22. Lindemann H (1987) Mukoviszidose und präkapilläre pulmonale Hypertension. Monatsschr Kinderheilkd 135:728–734

    PubMed  CAS  Google Scholar 

  23. Michael JR, Kennedy TP, Fitzpatrick S, Rosenstein BJ (1984) Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with cystic fibrosis and cor pulmonale. Am Rev Respir Dis 130:516–519

    PubMed  CAS  Google Scholar 

  24. Moss AJ, Harper WJ, Dooley RR, Murray JF, Mack JF (1965) Cor pulmonale in cystic fibrosis of the pancreas. J Pediatr 67:797–807

    PubMed  CAS  Google Scholar 

  25. Niznikowska-Marks J, Okninska A, Kaminski Z (1971) Fibrose myocardique au cours de la mucoviscidose. Helv Paed Acta 1:56–62

    Google Scholar 

  26. Nocturnal oxygen therapy trial group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Arch Intern Med 83:391–398

    Google Scholar 

Download references

Authors
  1. C. Aebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Bargon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Casaulta Aebischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Götz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Griese
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Kieselmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Kraemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Kriemler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Kusenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Liese
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H. Lindemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F. Ratjen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D. Reinhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. Riedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M. H. Schöni
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A. Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C. Vogelmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kinderklinik und Poliklinik im Dr. von Haunerschen Kinderspital der Ludwig-Maximilians-Universität, Lindwurmstr. 4, 80337, München, Deutschland

    Dietrich Reinhardt

  2. Abteilung für Kinder- und Jugendheilkunde, Wilhelminenspital der Stadt Wien, Montlearstr. 37, 1171, Wien, Österreich

    Manfred Götz

  3. Inselspital, Medizinische Universitäts-Kinderklinik, Freiburgstr. 23, 3010, Bern, Schweiz

    Richard Kraemer  & Martin H. Schöni  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Aebi, C. et al. (2001). Atemwegserkrankung. In: Reinhardt, D., Götz, M., Kraemer, R., Schöni, M.H. (eds) Cystische Fibrose. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56796-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56796-4_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63172-6

  • Online ISBN: 978-3-642-56796-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation